Published in final edited form as:

Anesthesiology. 2008 September ; 109(3): 543–564. doi:10.1097/ALN.0b013e318182c81b.

Intracarotid Delivery of Drugs: The Potential and the Pitfalls

Shailendra Joshi, M.D.* [Irving Assistant Professor of Clinical Anesthesiology], Phillip M. Meyers, M.D., F.A.H.A.# [Associate Professor], and Eugene Ornstein, Ph.D., M.D.* [Associate Professor]

*Department of Anesthesiology, College of Physicians and Surgeons of Columbia University, New York, New York

#Departments of Radiology and Neurological Surgery, College of Physicians and Surgeons of Columbia University, New York, New York

Abstract

The major efforts to selectively deliver drugs to the brain in the last decade have relied on smart molecular techniques to penetrate the blood brain barrier while intraarterial drug delivery has drawn relatively little attention. In the last decade there have been rapid advances in endovascular techniques. Modern endovascular procedures can permit highly targeted drug delivery by intracarotid route. Intracarotid drug delivery can be the primary route of drug delivery or it could be used to facilitate the delivery of smart-neuropharmaceuticals. There have been few attempts to systematically understand the kinetics of intracarotid drugs. Anecdotal data suggests that intracarotid drug delivery is effective in the treatment of cerebral vasospasm, thromboembolic strokes, and neoplasms. Neuroanesthesiologists are frequently involved in the care of such high-risk patients. Therefore, it is necessary to understand the applications of intracarotid drug delivery and the unusual kinetics of intracarotid drugs.

Introduction

For over fifty years, intracarotid anesthetic drugs have been used in diagnostic neuroradiology to locate brain functions.¹ In the 1980s intracarotid drugs were extensively investigated for the treatment of malignant brain tumors.^{2–6} However, the attempts at intracarotid chemotherapy of brain tumors proved disappointing because of unexplained neurotoxicity, and a relatively modest impact on the clinical outcome of the disease.^{7–9} Therefore the enthusiasm for intracarotid drug delivery waned by the early 1990s. Intracarotid injections can rapidly generate high concentration of drugs within a region of interest at a fraction of the total systemic dose.^{2,10} Consequently, intracarotid delivery can serve as the primary method of drug delivery or the technique could be used to increase the effectiveness of other methods of brain-selective drug delivery that target specific characteristics of the blood brain barrier (BBB).¹¹ Currently, intracarotid drugs are used for

Correspondence to be addressed to: Shailendra Joshi, M.D., Department of Anesthesiology, PH 505, College of Physicians and Surgeons of Columbia University, 630 West 168th Street, New York, NY 10032, Phone: 212-305-0021 Fax: 212-305-8287, sj121@columbia.edu.

Work attributed to: Department of Anesthesiology, College of Physicians and Surgeons of Columbia University, New York, New York

localizing neurological functions in the brain, and for the treatment of intractable cerebral vasospasm, ischemic strokes, and intracranial malignancies.¹²

In the last decade rapid advances have been made in endovascular neurosurgery. These include the development of microcatheters and small balloon occluding catheters, which can be floated into distal regions of the brain. These devices can selectively deliver drugs or manipulate blood flows, in relatively small vascular territories consisting of 40–100 g of brain tissue.¹³ The feasibility of intraarterial interventions on a limited scale decreases the risks of neurological complications. Improved techniques of intraarterial delivery have also recently emerged which compared to conventional infusions, can significantly augment tissue drug deposition.^{14–16} Magnetic resonance imaging with temporal resolution sufficient to guide catheter placement, described as “interventional magnetic resonance imaging”, is also rapidly advancing, and could lead to novel intraarterial interventions guided by the fast MR imaging and spectroscopy.¹⁷ Collectively, such technological advances compel us to reevaluate intracarotid drug delivery and ascertain its role in the current and future treatments of brain diseases.

An understanding of intracarotid drug delivery is important to anesthesiologists who are often involved in the care of patients receiving intracarotid drugs. This review rationalizes the use of intracarotid drugs, and describes their present and future applications. It also discusses anesthetic management of the current therapeutic interventions using intracarotid drugs.

Anatomic considerations

Some key anatomical features of the cerebral circulation affect intracarotid drug delivery to the brain. These include the size of the brain relative to the body weight, anatomical *configuration* of cerebral arteries, the state of the BBB, and the anatomical compartments within the brain.

The size of the brain relative to the body weight varies across animal species

In general, relative to the body size, the primates have a much larger brain weight than non-primate animals; and even amongst primates, the humans have a much greater brain to body weight ratio.¹⁸ As a result, primates can tolerate greater intracarotid doses of drugs based on body weight. For example, an intracarotid dose of 8 mg/kg of an anti-neoplastic drug, carmustine, produces severe hemorrhaging necrotizing lesions in dogs but the same dose is well tolerated in rhesus monkeys and in humans.^{19–21}

The configuration of cerebral arteries

Anatomical variations of the cerebral arteries can influence regional distribution and concentration of drugs after intracarotid delivery. The configuration of cerebral arteries varies (a) across animal species,²² (b) within individuals of the same species or (c) even in an individual over time.

The extent of communication between the external carotid artery and the internal carotid artery (ICA) greatly varies across animal species. Rabbits and the primates show a clear

separation of the intracranial and extracranial irrigations.^{23–25} On the other hand, many animals such as goats and pigs, have extensive collateral communications between the intracranial and extracranial arterial irrigations.²² Even within animals of the same species there can be significant differences in the origin and the size of the ICAs.²⁴ Smaller animals have larger external carotid artery and the sizes of the ICAs, relative to the vertebral arteries, differ across species. Thus, ICA occlusion is fairly well tolerated in rodents and causes a transient decrease in blood flow in rabbits.²⁶ However, ICA occlusion often causes neurological symptoms in humans.^{27,28} The ability of the human subjects to tolerate ICA occlusion depends largely on the configuration of the Circle of Willis. Only 18% of human subjects have a balanced symmetrical Circle of Willis, (fig. 1), therefore there is the need to clinically test if a patient can tolerate ICA occlusion prior to ICA sacrifice.^{29–31} The configuration of the Circle of Willis also determines the resistance of each arterial segment that could influence the distribution of intracarotid drugs.³²

Furthermore, the blood flow in a given artery can change with time which could affect the regional tissue concentrations of intracarotid drugs. It has been shown that the pharmacological effects of intracarotid drugs, such as anesthetics, are directly related to CBF.^{33,34} If changes in blood flow have a significant effect on tissue drug concentrations then, the arterial concentrations generated after injection of the same dose of a drug might be different over time even in the same individual. Consider for example super-selective intracarotid infusion of papaverine for cerebral vasospasm. Initially, when blood flow is low, the concentration of the drug is high due to minimal dilution with arterial blood. As vasospasm resolves, blood flow increases and arterial concentration declines due to greater dilution.³⁵ In theory, the vasodilatory effects of intracarotid drugs that augment local blood flow, may paradoxically decrease regional deposition of the drugs.³³

The BBB

The BBB is primarily constituted by tight junctions between the endothelial cells that severely restrict migration of molecules from the blood into the brain tissue. In other capillary beds, there are clefts between the endothelial cells that permit passage of molecules. However, in the brain the tight endothelial junctions permit only transcellular migration of molecules, either by diffusion, carrier transport or rarely by pinocytosis.^{36,37} Abnormalities of endothelial tight junctions are seen with brain tumors and could be responsible for tumor related brain edema.³⁸ Morphologically, endothelial cells of brain arteries compared to other regions of the body, are rich in mitochondria. These mitochondria are also larger in size. This suggests that endothelial cells are metabolically very active.^{39–41} Endothelial cells also are rich in metabolic enzymes such as catecholamine methyl-transferase, mono-amine oxidase, and adenosine deaminase,⁴² which create a chemical barrier to drugs, such as catecholamines and adenosine.⁴³ In general, small non-polar lipid soluble drugs can easily penetrate the BBB by passive diffusion. In contrast, the effective delivery of macromolecules that include anti-neoplastic drugs and nucleotides, is possible only when the BBB is disrupted.⁴⁴

Physiological compartments in the brain

The brain is best described in terms of three compartments: blood, cerebral spinal fluid (CSF) and brain parenchyma. The brain tissue itself can be further divided into gray and white matter. Additional compartments might be created within the brain parenchyma which have their own kinetic characteristics in pathological states (fig. 2).¹⁰ Consequently, under physiologic conditions, there are three interphases between the compartments in the brain of which the BBB is the most significant.⁴⁴ The BBB has been regarded as the gate-keeper to the brain. Compared to the blood-CSF interphase, the BBB has 5000-fold greater area and has much lower permeability.⁴⁵

Kinetics of intracarotid drug infusions

Figure 3 shows the simple kinetic framework described by Dedrick et al. demonstrating the advantage of intracarotid injection.¹⁰ If C_1 and C_2 are the regional and systemic drug concentrations, the pharmacokinetic advantage of intracarotid (ic) over intravenous (iv) infusion can be defined as:

$$R = (C_1/C_2)_{ic} / (C_2/C_1)_{iv},$$

In figure 3, I is the rate of drug infusion; Q , the regional blood flow; E , the first pass extraction of the drug from the region; CL_1 and CL_2 , the clearances from the region and from the rest of the body. CL_{TB} is clearance from the whole body ($CL_1 + CL_2$). R can also be derived as:

$$R = 1 + CL_{TB} / Q(1 - E) \quad (\text{Equation 1})$$

If $CL_1 = 0$ then,

$$R = 1 + CL_{TB} / Q \quad (\text{Equation 1a})$$

Conversely if $CL_2 = 0$ then,

$$R = 1 / (1 - E) \quad (\text{Equation 1b})$$

Equation 1 and its derivatives 1a and 1b show that the maximum advantage of intracarotid drug infusion is evident with (i) drugs that have high CL_{TB} , or (ii) when the regional arterial flow (Q) is low or (iii) when the regional extraction is high. For example, we can illustrate the advantage of intracarotid delivery of propofol using equation 1a. Assuming an ICA flow to be 200 ml/min and CL_{TB} of propofol to be 2100ml/min for 70 kg individual, then R propofol will be, $1 + 10.5 = 11.5$. This theoretical number is fairly close to the observed experimental results showing a 10-fold reduction in dose of propofol required to produce electrocerebral silence with intracarotid delivery compared to intravenous infusion.⁴⁶ Conversely, the possibility of achieving high intracarotid concentrations also suggests that

intracarotid infusion might result in locally toxic drug concentrations without any evidence of systemic toxicity.

Pitfalls in kinetic modeling of intracarotid drug infusions

There are several assumptions in the kinetic model proposed by Dedrick et al.¹⁰ These include: uniform mixing of drug in the blood, determining free drug concentration based on conventional steady state drug-protein interactions, constant clearances over time, constant regional blood flow, homogenous distribution within the arterial irrigation and homogenous behavior of the brain compartment. Two of these assumptions merit close scrutiny:

a. Estimation of the free drug concentration after intracarotid injection of the drug—According to the “free-drug hypothesis,” it is the free drug in the plasma that is available for diffusion across the BBB. However, *in-vivo* during intracarotid injections, the tissue brain concentrations are higher than those predicted by the free-drug hypothesis. Jones et al. compared the uptake of different benzodiazepines after intracarotid bolus injection in rats.⁴⁷ They found that the brain uptake of this class of drugs was largely determined by their lipophilicities. However *in-vitro* modeling grossly underestimated the *in-vivo* uptake of these drugs. They determined that observed *in-vivo* data deviated from the more theoretical model with higher doses of albumin that were injected along with the drug. The free drug concentration seemed to be 5 to 25-fold greater *in-vivo* than predicted by *in-vitro* observations.⁴⁷ Several possible explanations have been offered for this observation. First is the “free-intermediate hypothesis” which states that rapid uptake of a drug into the brain enhances the release of drug bound to plasma proteins.^{48,49} The second possibility is that other proteins in the blood have higher drug affinity, such that *in-vitro* estimates of free drug concentrations based on albumin binding alone underestimate the blood concentrations.^{49,50} The third possibility is that there might be some drug-protein binding competitor in the capillaries that increases the drug-protein dissociation rate.⁵¹ Fourth, when drugs bind to the proteins they are absorbed by a peptide transporter system which may increase transfer across the BBB.⁵²

b. Heterogenous nature of brain compartments—It is best to consider the brain parenchyma in terms of separate compartments with distinct units as described above: (i) gray matter, (b) white matter and (c) pathological compartments, such as tumor or ischemic regions, within the brain parenchyma.^{53,54} These compartments will differ with respect to their blood flow, BBB functions and their ability to extract and metabolize drugs. For example the blood flow to the gray matter (50 ml/100g/min) is approximately 2-fold greater than in the white matter (25 ml/100g/min) and four fold greater than in the ischemic regions (12 ml/100g/min).⁵⁵ Baseline variability in regional blood flow could result in differences in drug concentrations in the brain tissue compartments following intraarterial injection.¹⁰ Eventually, effective modeling of intracarotid drug delivery will require an understanding of the micro-pharmacokinetic factors that determine drug distribution within the brain tissue (fig. 4).⁵⁶

Theoretical advantages of intracarotid drug delivery

Intracarotid infusion of drugs offers the following theoretical advantages:

High regional arterial concentration

Intracarotid drug infusion can restrict the initial volume of distribution to one cerebral hemisphere. The volume of blood flow through the ICA in humans has been estimated to be approximately 200 ml/min whereas the cardiac output is 5–6 l/min. Consequently, drugs that are infused into the small volume of ICA flow achieve relatively high initial arterial concentrations at low total doses, thereby decreasing systemic toxicity.^{46,57,58}

High free drug concentrations

Although the exact nature of the interactions between the drug and binding proteins after intracarotid infusions remains to be fully understood, limited data suggest that intracarotid administration of drugs results in disproportionately *higher free drug* concentrations than those predicted by steady state kinetic models.⁴⁷ Recent videomicroscopic images have revealed that bolus injections of drugs transiently overwhelm the blood flow and may deliver virtually undiluted drug to the brain.⁵⁹ Such injections, in theory, would considerably attenuate the decrease in free drug concentration due to protein binding or the uptake by blood cells. Manipulating the key parameters of bolus injection, volume, concentration and frequency can have a significant effect on the tissue concentrations of intracarotid drugs.⁵⁹ Bolus injections when combined with regional blood flow manipulation could therefore significantly enhance intracarotid drug delivery.³⁴

Rapid onset of action

Intracarotid delivery can achieve *rapid*, virtually instantaneous, high drug concentrations in the brain. Such an ability to instantaneously generate high tissue concentrations may be critical in some clinical situations, such as, preventing reperfusion injury after intracarotid thrombolysis.^{60–62}

Theoretical disadvantages of intracarotid drug delivery

The theoretical disadvantages of intracarotid infusions can be summarized as:

The high resting CBF as a disadvantage

As the target organ the relatively high resting blood flow to the brain, that amounts to 15–20% of the cardiac output, is a disadvantage compared to some other less well perfused organs.⁶³ High blood flow decreases the peak drug concentrations due to greater dilution by the arterial blood. Increased blood flow to the brain could decrease the drug transit time through cerebral circulation if the cerebral blood volume was not proportionately increased. Transit time seems to have a direct effect on tissue concentrations of highly lipid soluble anesthetic drugs after intracarotid injections.⁵⁶ In addition, high blood flow will augment drug efflux from the brain tissue.

Kinetics of intracarotid drugs are difficult to model

For example, under physiological conditions, the brain has at least three compartments: gray matter, white matter and cerebrospinal fluid. These compartments demonstrate unique kinetic characteristics. Pathological tissue, such as cerebral edema or brain tumor, may have significantly different kinetic properties. These factors may make it difficult to model drug

kinetics in physiological and pathological states and has led to the failure of theoretical models of intracarotid drug delivery.⁶⁴

Loss of intracarotid dose advantage over time

The advantages of intracarotid vs. intravenous drug delivery decrease with prolonged infusions due to lower peak regional concentrations and the eventual redistribution of the drug. Computer simulations suggest that intracarotid drug infusion over 2 hours vs. the same dose infusion over 10 hrs, results in regional concentrations that are 5.5 and 3.1-fold greater than intravenous delivery, respectively.¹⁰ Experiment data also suggest that the comparative dose advantages of intracarotid versus intravenous drug delivery decrease when infusions are used for prolonged periods of time. In rabbits, intracarotid propofol achieves transient electrocerebral silence at one-tenth the IV dose. On the other hand, to maintain electrocerebral silence for 1-hour, intracarotid delivery is only 5-fold as effective as the intravenous injection.⁴⁶

Brain tissue drug concentration measurements are challenging

Measurements of drug concentrations are particularly challenging with intracarotid drug delivery to the brain. Post mortem samples do not provide time histories.⁶⁵ Multiple tissue biopsies, though feasible, tend to injure the preparation and are not site-specific.⁶⁶ Insights into the field have been limited to a few magnetic resonance imaging Positron Emission Tomography and a few radio-labeled drug based studies.^{47,67–70} The α -half-life of many lipid soluble drugs such as carmustine and propofol is exceedingly short, ranging between 1.4 to 7 min.^{68,71} Microdialysis requires time to obtain sufficient sample for analysis, is invasive and may alter tissue characteristics.^{72,73} Thus, the exceedingly rapid changes in tissue drug concentrations, particularly after bolus injections, are beyond the time resolution of microdialysis. Novel optical techniques, such as diffuse reflectance spectroscopy, can noninvasively measure tissue drug concentrations in virtual real-time which could provide better understanding of intracarotid drug kinetics.^{74,75}

Practical methods to improve intracarotid drug delivery

From the practical standpoint intracarotid drug delivery could be improved by the following means:

Disrupting the BBB

Controlled disruption of the BBB can be achieved either by (i) hyperosmotic agents, or (ii) by chemical means.^{76,77}

Hyperosmotic disruption

Intracarotid injection of hypertonic substances such as mannitol and arabinose leads to a transient loss of BBB functions (fig. 5).⁷⁸ Hypertonic agents cause vasodilation and shrinkage of the endothelial cells, resulting in increased diffusivity and bulk flow across the BBB.⁷⁷ Cell shrinkage along with the contraction of the endothelial cytoskeleton, results in widening of the tight junction to about 20nm that result in a ten-fold increase in permeability of some compounds. Alternately, some believe that mechanisms other than cell shrinkage,

such as alterations in $\text{Na}^+/\text{Ca}^{++}$ exchange might play a role during osmotic disruption of the BBB.⁷⁹ The effects of hypertonic mannitol were previously thought to be exceedingly transient although data suggest that in humans hypertonic BBB disruption lasts for 30 minutes and that BBB functions remain impaired for several hours afterwards.⁸⁰ Zunkeler et al. showed that the healthy BBB was almost 15-fold more susceptible to osmotic disruption than the BBB in glioma tumors.^{81,82} Biomechanical factors such as systemic hypotension seem to mitigate osmotic disruption of the BBB, while hypertension enhances disruption.^{83,84} In experimental settings, the efficacy of hypertonic mannitol can also be enhanced either by cooling the solution to 4°C or with a $\text{Na}^+/\text{Ca}^{++}$ exchange blocking drug, KB-R7943.^{85,86} There is evidence to suggest that treatment with steroids, anesthetics and magnesium can mitigate BBB disruption by intracarotid mannitol.^{87–90} Restoring BBB functions after intracarotid mannitol may help in limiting the complications of hypertonic mannitol therapy.^{88,91–93}

Chemical disruption of BBB

Chemical disruption of BBB by intracarotid injection of bradykinins such as cereport (RMP-7) or leucotrienes (LTC-4) results in transient opening of the BBB.⁷⁶ Contrary to the disruption by mannitol, disruption of the BBB by cereport and leucotrienes seems to be limited to pathological lesions and not normal brain. The effects of the drug are reversible within 30–60 minutes. Cereport can increase the uptake of intra-arterially delivered antineoplastic drugs.^{94,95}

Superselective intracarotid delivery of drugs

One of the ways to minimize the side-effects of intracarotid drugs is to restrict their delivery to pathological lesions by superselective cannulation of the feeding arteries. With the development of highly flexible flow directed catheters with external diameters of 1.5–2 mm, it is possible to cannulate distal branches of the carotid artery without the risk of obstructing the blood flow (fig. 6).⁹⁶ The problem with distal cannulation is the increased risk of streaming, see below.⁹⁷ However, side port catheters and diastolic pulse delivery can minimize the chances of streaming.⁹⁸ The theoretical advantages of super-selective delivery of drugs include: minimizing the total dose, decreasing the risk of regional toxicity, and limiting potential vascular complications to the pathological regions of the brain. In case of intracarotid vasodilators, super-selective infusions will decrease the chances of cerebral steal or the likelihood of an increase in intracranial pressure. A key concept recently introduced by Gobin et al., was to determine the dose of intracarotid drugs based on a spatial fractionation algorithm.¹⁴ The algorithm calculates the intracarotid dose requirements during super-selective drug injections based on the volume of tissue perfused by a given intracranial artery. Such an approach decreases the risks of neurological complications during intracarotid chemotherapy.

Localizing the drug effects

Intracarotid infusions can be further targeted to the brain by enhancing their *removal from the systemic circulation*, by extra-corporeal removal, forced alkaline diuresis, or by neutralizing the effects of a drug by the co-administration of a systemic antidote.^{3,99} The use

of drugs, such as adenosine, with exceedingly short biological half-lives, greatly minimizes the risks of systemic side-effects, and could potentially lead to “*fire-and-forget*” types of intraarterial drug interventions.⁵⁸

Manipulating CBF to increase drug delivery

Early computer simulations had shown that intracarotid drug delivery to the brain is particularly useful in low blood flow states.¹⁰ In a series of experiments, CBF was altered either by changing ventilation, or by augmenting blood flow with intracarotid verapamil pretreatment, or by producing transient flow arrest. The dose of an intracarotid anesthetic, propofol, required to produce electroencephalographic silence, was directly related to the blood flow.³³ Both hypercapnia and verapamil pretreatment which increased CBF, increased the dose requirements of intracarotid anesthetics, while flow arrest significantly increased the duration of electroencephalographic silence after bolus anesthetic injection (fig. 7 and 8).^{33,34}

Practical considerations with intracarotid drug delivery

There are several significant practical concerns with regard to intracarotid drug delivery to the brain:

The risk of embolism and hemorrhage during endovascular interventions

Recent review suggests that the incidence of neurological complications after endovascular procedures varies a great deal from 5.6% during the placement of a carotid stent to 19% during occlusion of a parent artery in the treatment of cerebral aneurysms.¹⁰⁰ A significant factor contributing to this morbidity is cerebral embolism due to thrombi, dislodged atheromatous plaques or air emboli. A number of strategies are being developed to interrupt the thromboembolic pathway. Soft, flow guided catheters can decrease the risk of endothelial injury. Adhesion, activation and aggregation of platelets can be inhibited with agents such as aspirin, ticlopidine and clopidogrel. The coagulation cascade can be blocked by inhibiting the activation of fibrinogen by thrombin. The anti-thrombin effects (as well as the potential adverse effects) of heparin are well known, can easily be monitored by measuring the activated clotting time, and can be easily reversed with protamine. Thus, heparin provides convenient thromboembolic prophylaxis in clinical settings. Although heparin has been the mainstay of thromboembolic prophylaxis during endovascular surgery, newer strategies such as hirudin analog or platelet receptor antibodies may find wider application in the future.¹⁰¹ Endovascular interventions in the background of significant anticoagulation, carry a greater risk of hemorrhagic stroke as a complication. Catastrophic bleeds during the procedure require immediate and aggressive endovascular and surgical interventions. Rapid reversal of the anticoagulant effects of heparin with protamine is particularly useful in such situations. A well thought out management strategy should be in place prior to anticoagulation.¹⁰²

The risk of thromboembolism is also directly related to the duration of endovascular catheterization. Prolonged catheterization of the cerebral arteries can permit repeated cerebral angiography to monitor response or facilitate delivery of drugs. Retrograde

cannulation of the superficial temporal arteries was used to permit cerebral angiography over a week without any complication in patients with intracranial aneurysms.¹⁰³ Kallmes et al. have used a swine model to demonstrate that catheters with hydrophilic surfaces were less thrombogenic than those with hydrophobic surfaces.¹⁰⁴ The risk of thromboembolism also depended on the catheter material not just surface coating. In this model long term implantation of a microcatheter was well-tolerated for the longest duration of the study, 35 days.

Air embolism

One of the less recognized risks of intracarotid drug therapy is the accidental injection of air, sometimes dissolved in fluids. Studies with transcranial Doppler flow measurements have revealed a frequent occurrence of microscopic air emboli during angiography. Microscopic air entrainment is likely to occur at two times during the angiographic procedure; during the aspiration of contrast into the syringe and during the injection of contrast. Increased viscosity of contrast increases the risk of air entrainment. The chances of air emboli being injected are decreased if the syringes are allowed to stand. The risk of air embolism is directly related to the rate of injection and inversely related to its viscosity. Thus decreasing the rate of injection decreases the chances of air embolism.¹⁰⁵

Streaming of drugs

Streaming of drugs refers to the uneven distribution of drugs in the arterial stream that results in different drug concentrations within that arterial distribution.¹⁰⁶ Streaming has been observed *in-vivo* and *in-vitro*, and has been invoked to explain focal drug toxicity of chemotherapeutic agents within arterial distribution (fig. 9 and 10). Using a polystyrene cast of human cerebral arteries, it has been shown that streaming depends on the rate of drug infusion, the type of catheter used for drug delivery, and the position of the catheter in relation to the arterial branching. This *in-vitro* model suggests that there can be almost 5-fold differences in drug concentrations due to streaming.¹⁰⁷ In a human study using O¹⁵ Positron emission tomography, Saris et al. demonstrated that there can be an 11-fold variation in regional drug concentration within the arterial irrigation of the supraorbital segment of the ICA.⁹⁸

Local vs. systemic toxicity

The delivery of drugs directly into the brain has been associated with regional toxicity. There is an increased incidence of white matter lesions with intracarotid chemotherapy compared to intravenous therapy.^{108,109} Streaming is also thought to be responsible for retinal injury after intracarotid infusion of antineoplastic drugs.¹¹⁰ Thus, in defining toxicity one has to factor in the total dose of the intra-arterial drug, as well as the highest possible concentration that might result from inadequate mixing. In addition, possibility of injury to blood vessels, such as to the vascular endothelium, should also be considered.^{111,112}

Standardizing the dose of intracarotid drugs

One of the major problems in intracarotid drug therapy is the standardization of doses within individuals of the same species or during the extrapolation of data between animals of

different species. Doses have been described in terms of weight/unit body surface area,¹¹³ total mg dose, or infusion rates in mg/min, and dose/kg body weight. Investigators have also assessed the response to intracarotid drugs as a function of estimated molar concentrations.^{114–116} In the absence of any consistent way to present dose-data, it is sometimes difficult to compare drug-response in different studies. We recommend that to optimally interpret intracarotid dose-response data, one has to consider all three infusion parameters: (i) The rate of drug infusion (mg/min, or moles/min), which along with the blood flow, determines peak concentrations. (ii) Estimated concentration in arterial blood i.e., dose of drug/volume of blood flow in the infused artery. With superselective infusions drug concentrations may be estimated by the volume of tissue infused based on angiographic measurements.¹¹⁷ (iii) The total dose when it is sufficient to cause systemic toxicity.

The exact description of intracarotid doses is particularly important in extrapolating the doses from one animal species to another. Due to the differences in relative sizes of various organs, scaling of intracarotid doses merely on the basis of body weight or body surface area can lead to errors. For example, within individuals of a given species, parameters such as blood flow in the internal carotid artery, can be assumed to be relatively constant, but across animal species those assumptions may not be valid. Thus, the same amount of drug will generate different arterial blood concentrations. Due to the relatively large size of the brain and higher carotid arterial blood flow, primates tolerate a much higher dose of intracarotid drugs compared to rodents or dogs. To undertake intra-species comparisons, Dedrick et al. described kinetic models based on organ size and surface areas.¹¹⁸ These relative sizes of organs differed between species but their function and surface characteristics were similar. Even when such allometric corrections are made, it is still difficult to project intracarotid kinetic data from one animal species to another.

Clinical use of intracarotid drugs

Intracarotid anesthetics for the localization of brain functions

Over 50 years ago Wada developed the technique of injecting *sodium amytal* into the carotid artery.¹ The procedure was originally developed to permit unilateral electroconvulsive therapy but subsequently became a standard method for localizing language function and memory. Other anesthetic drugs that have been used for Wada testing, include *methohexitone*, and recently *propofol*.^{1,119–122} Compared to amytal, intracarotid methohexitone seems to have a shorter duration of effect, thereby making it possible to test multiple arterial territories in the same setting.¹²² However, there seem to be poor justification for the selection of intracarotid doses.⁷¹ Most radiologists use a graded dose of 75–125 mg of amytal mixed with contrast media. After an initial dose of 75 mg, additional boluses of 25 mg are injected until there is an upper limb drift. Speech, language and memory functions are assessed as the deficit resolves. Intracarotid amytal in doses as high as 3 mg/kg or 200 mg, has been used during the Wada test. Such high intracarotid doses of anesthetic drugs on recirculation suppress the contralateral hemisphere. Any additional baseline sedation provided by an anesthesiologist in attendance would further complicate the interpretation of the Wada test. Therefore, it has been recommended that when high doses of amytal are used, the contralateral hemisphere should be tested on a subsequent day.¹²³

In recent years there has been considerable interest in the use of propofol for Wada testing.¹²⁰ In a recent study however, as many as 19 out of 58 patients developed transient neurological symptoms. These consisted of tonic movement, confusion, and pain. The complaints were seen when more than 10 mg of the drug was rapidly injected in patients over 55 years of age. None of these patients suffered any permanent complication but the authors recommend limiting the dose of propofol to 10 mg and careful monitoring in patients above 55 years of age.¹²⁴ Despite these recent reports with propofol, the safety of Wada is underscored by the fact that the test has been widely used for a very long time. Although neurological complications have been reported due to arterial emboli, they do not seem to be frequent.¹²⁵

A super-selective Wada testing is also used prior to embolization of cerebral arteriovenous malformations (fig. 11). Because embolization of the lesion could injure both gray and white matter, injection of amytal is combined with injection of lidocaine in order to test for both the gray and the white matter. Amytal is injected first to suppress gray matter activity, followed by the injection of lidocaine to suppress nerve conduction through the white matter. Anesthesiologist involved in the care of patients undergoing Wada tests, should employ judicious amounts of sedation. Both propofol and dexmedetomidine have been used for the purpose. Midazolam may impair memory testing therefore has to be cautiously used.

Cerebral Vasospasm

Cerebral vasospasm is a pathological narrowing of the cerebral arteries. The fundamental method to overcome this added arterial resistance, whether proximal or distal, is to increase the cerebral perfusion pressure and the cardiac output by employing hypervolemic-hemodilution with induced hypertension (triple-H treatment).¹²⁶ A significant number of patients with cerebral vasospasm fail to respond to the triple-H treatment. Furthermore, triple-H has to be carefully applied to patients with untreated or multiple aneurysms. The alternate strategy in such cases is to decrease cerebrovascular resistance by superselective intracarotid or intracarotid infusion of vasodilators.^{58,117,127,128} Intracarotid papaverine has been the mainstay of such a treatment, although a variety of drugs such as *calcium channel blockers*, *mannitol*, and *prostaglandin E* have also been used intraarterially for treating vasospasm (fig. 12). Other drugs such as adenosine have been proposed for the treatment of vasospasm, and despite their significant vasodilator effects, have not yet been used in clinical settings probably due to their short duration of effect and poor penetration of the BBB (fig. 13).

Table 1 shows the published outcomes of intracarotid vasodilator therapy. Clinically about 30–60% patients seem to benefit from intracarotid vasodilators. Angiographic improvement however, is seen much more frequently. Although there is a suggestion that intracarotid vasodilators may augment CBF, improve cerebral oxygenation and reverse metabolic acidosis, the effect of vasodilator therapy seems to be transient and resolves completely over the next 24 hours. By measuring the time it takes for radiocontrast to transit through the cerebral arteries and the capillary bed, one can estimate the differential effects of intracarotid vasodilators on the proximal and distal cerebral circulation. In the case of

papaverine, the resistance of both the proximal and distal cerebral arteries decreases during drug infusion.^{35,128}

Intracarotid vasodilator therapy carries with it two general risks: (a) cerebral steal and (b) increase in Intracranial pressure (ICP). However, neurological complications can also result from specific drugs, e.g., neurotoxicity with papaverine.¹²⁹

Cerebral steal has been invoked to explain the decrease in regional blood flow in proximity to focal cerebral pathology following the administration of intravenous or intracarotid papaverine.^{130,131} Any decrease in hemispheric cerebrovascular resistance whether pathological or iatrogenic, can cause a redistribution of blood flow away from those ischemic areas where there is already maximal vasodilation. In recent years, the clinical significance of steal has been challenged as with regard to large arteries.¹³² There are, however, examples of microcirculatory steal during hypercarbia or during administration of volatile anesthetic agents, such as halothane, in the setting of focal cerebral ischemia.^{133,134} Unless vasodilator therapy is restricted to the arteries afflicted by cerebral vasospasm, intracarotid vasodilator therapy carries the theoretical risk of cerebral steal, due to vasodilation in the normal vascular beds.

Increase in ICP—Increase in ICP has been reported with intracarotid infusion of papaverine. Controversy surrounds the effect of intracarotid vasodilators on ICP. Experiments on dogs and monkeys who do not have cerebral vasospasm, suggest that intracarotid vasodilators like sodium nitroprusside increase ICP, but may not increase CBF, implying that nitroprusside affects cerebral capacitance arterioles to increase cerebral blood volume with no effect on the resistance arterioles.¹³⁵ On the other hand, intracarotid infusion of adenosine has a relatively benign effect on ICP, but augments CBF suggesting that adenosine primarily affects the resistance arterioles.¹³⁶ It remains to be seen if intracarotid therapy could selectively target proximal or distal cerebral arteries to minimize the risk of increased ICP.

Cross et al. measured changes in ICP during intracarotid infusion of papaverine in 28 patients. The increase in ICP ranged from 0–60 mm Hg. A baseline ICP 15 mm was associated with a greater risk of increasing ICP. However, Hunt and Hess scores, Fisher grades, age, and Glasgow Coma Scale scores on admission and immediately before treatment did not correlate with ICP increases. ICP increases result in a decrease in cerebral perfusion pressure. Therefore, hypertensive-hypervolemic interventions need to be continued during intracarotid vasodilator infusions. ICP should be monitored during intracarotid vasodilator therapy whenever feasible.¹³⁷

Intracarotid papaverine—Papaverine is perhaps the most potent cerebral vasodilator. Papaverine acts through several intracellular pathways which include: Cyclic guanosine monophosphate, Cyclic adenosine monophosphate, phosphodiesterase inhibition, Ca^{++} channel blockade and histamine release. Table 1 summarizes the efficacy of papaverine and other vasodilators in the settings of cerebral vasospasm. Intracarotid papaverine can relieve angiographic narrowing, augment CBF and mitigate neurological symptoms in patients with cerebral vasospasm resistant to medical treatment. Typically, during the treatment of

cerebral vasospasm a dose of 300 mg of papaverine is infused over 1 hour.¹³⁸ Unfortunately, intracarotid papaverine infusion also results in significant neurological complications,¹³⁹ attributable to several factors: cerebral steal, increased intracranial pressure,^{137,140} micro-embolization of papaverine crystals,^{141,142} neurotoxicity of the preservative (chlorobutanol)¹⁴², pro-convulsive properties of the drug,¹⁴³ and paradoxical vasoconstriction¹⁴¹.

Cerebral steal, i.e., redistribution of blood flow away from the ischemic region, has often been implicated in the etiology of neurological symptoms following intravenous or intracarotid administration of papaverine.^{130,144} There is evidence that intravenous papaverine increases blood flow in ischemic regions of patients with cerebrovascular insufficiency.¹⁴⁵ However, experiments on cats with middle cerebral artery occlusion suggest that steal does not always occur with cerebral vasodilation. Intravenous papaverine in the feline middle cerebral artery occlusion model did not decrease regional CBF to ischemic areas as long as the blood pressure is maintained.¹⁴⁶

Intracarotid calcium channel blockers—Intracarotid calcium channel blockers have been used to treat cerebral vasospasm for over a decade, however, their intracarotid administration is still not considered to be the mainstay for the treatment of cerebral vasospasm. Intracarotid verapamil, nicardipine and nimodipine have been used for the treatment of vasospasm (table 1). There are no human studies as yet which compare the relative potencies of calcium channel blockers against papaverine. However, studies in similar groups of patients who do not have cerebral vasospasm, suggest that compared to papaverine, intracarotid verapamil seems to be less efficacious in augmenting CBF. Verapamil in small doses (3 mg) results in angiographic improvement without systemic hypotension, although only 5/29 patients in this retrospective study improved clinically.¹⁴⁷ The modest efficacy of the calcium channel blocker might still be advantageous because it is likely to decrease the risk of cerebral steal or increasing ICP. Experimental vasospasm triggered by topical application of endothelin-1 seems to be more responsive to intracarotid nicardipine than verapamil.¹⁴⁸ Intracarotid nicardipine is effective in reversing cerebral vasospasm, but no study has as yet compared the potency of the various intracarotid calcium channel blockers.¹⁴⁹

Intracarotid prostaglandins—Recently, intracarotid infusions of liposomes with papaverine and prostaglandin E2 have been used for the treatment of cerebral vasospasm. Two-thirds of the patients demonstrated an increase in CBF after such a treatment.¹⁵⁰

In order to enhance the clinical efficacy of intracarotid vasodilators and decrease the risks of complications, a number of adjuvant strategies have been suggested. First, transluminal *angioplasty* has been used to treat cerebral vasospasm when it affects the ICA or the proximal segment of the middle cerebral artery. Angioplasty, compared to intracarotid drugs, results in a more profound and persistent increase in blood flow but it can only be used in the proximal arteries. Drugs such as papaverine are therefore useful in treating distal spasm and could be of benefit even after angioplasty.¹²⁸ *Hypothermia* has also been used to provide brain protection and increase the time window for intracarotid vasodilator therapy.¹⁵¹ Techniques of selective brain cooling either by the infusion of cold saline or by

endovascular cooling devices are currently being developed to minimize injury after vasospasm and ischemic stroke.^{152–154} Finally, *cocktails of vasodilators* have been used so as to increase both the potency and duration of effects of intracarotid vasodilators. Thus, papaverine has been used in conjunction with nimodipine, nicardipine, prostaglandins to enhance its safety and efficacy.¹⁵⁰

The key in the anesthetic management of patients for intracarotid vasodilator treatment is to recognize the potential for exacerbating neurological injury. These patients may present either with untreated ruptured aneurysms or after clipping of the lesion. At many institutions triple-H therapy is instituted prior to intracarotid vasodilator therapy. Patients with subarachnoid hemorrhage may require inotropic support due to impaired myocardial functions secondary to hemorrhage. Ideally, management of these cases requires monitoring of the ICP so as to treat any increase either by mechanical drainage, hyperventilation, or supplemental intravenous anesthesia. Furthermore, due to recirculation of intracarotid vasodilators there may be significant systemic hypotension. Therefore, anesthesiologists should be prepared to induce hypertension so as to ensure adequate perfusion pressure.

Cancer chemotherapy

The major driving force for the development of intracarotid therapies in the 1980s was the treatment of brain neoplasms. However, it soon became evident that the BBB prevented effective transfer of chemotherapeutic agents.² Thus, attempts to disrupt the BBB began fairly early on.^{77,94} Currently, intracarotid chemotherapy is used for the treatment of primary central nervous system lymphoma, primitive neuroectodermal tumor, germ cell tumor, cancer metastasis to the brain, or low or high grade glioma (fig. 14).¹¹¹ The initial response to intracarotid chemotherapy is impressive with as many as 70–81% tumors regressing, occasionally with a significant prolongation of survival.^{155,156} However, most studies have been anecdotal or uncontrolled case series. The major concern of intracarotid therapy is unexplained local toxicity, likely attributed to unusually high concentrations of the drug due to streaming. One strategy that has minimized streaming is using pulsed intracarotid infusion which delivers the drug in the diastolic phase of cardiac cycle to increase mixing.^{106,157}

The role of regional blood flow in enhancing intracarotid delivery of chemotherapeutic drugs is ill understood at this time. Some groups have suggested an increase in drug doses in proportion to the regional blood flow, so as to safely achieve higher total doses and better tumor regressions.^{14,156} At the same time it has recently been shown that transient decrease in CBF could significantly increase delivery of anticancer drugs to the brain in a rabbit model.¹⁵ Thus, the exact role for the manipulation of CBF in enhancing cancer drug delivery remains to be fully understood at this time. The fundamental problem confronting investigators is the inability to rapidly measure tissue concentrations of chemotherapeutic drugs. Insights into intracarotid delivery of some anticancer drugs could be generated by optically tracking their concentrations in the brain tissue by novel spectroscopic techniques.^{75,65,74}

The disruption of the BBB with intracarotid mannitol that is often needed to improve regional delivery of anti-cancer drugs also carries significant clinical risks.¹⁵⁸ Due to pain

associated with the procedure, the disruption is undertaken under general anesthesia. In a recent report involving 17 patients and 210 treatment cycles, focal seizures occurred in 9 patients and in 10% of the treatment cycles. In some case these seizures were generalized (2 patients and 3% treatment cycles). Chances of seizure were higher with intracarotid than vertebral artery injections. Impaired consciousness was seen in 7.6% patients with recovery in 24 hours. One patient in this series had an intractable increase in ICP requiring decompressive hemispherectomy a day after treatment. Attempts to augment CBF to enhance drug delivery with intravenous atropine probably contributed to ST segment changes seen in 4.3% of the cases, requiring beta blockade. Other complications included transient neurological deficits (6%), post-operative nausea and vomiting despite 20 mg of ondansetron (11.9%) and headache (4%). Management of these patients requires a well thought out plan to include close monitoring of the patient's neurological and hemodynamic status and to address significant complications that arise in the post-operative periods.¹⁵⁹ Patients with brain tumors may require pre-operative embolization with n-butylcyanoacrylate (NBCA glue) to decrease blood loss during surgery (fig. 15). These procedures are relatively painless and can usually be done with minimal sedation.

Intracarotid thrombolysis for stroke

The object of intracarotid thrombolysis is to deliver high concentrations of thrombolytic drugs locally into the brain.¹⁶⁰ Intravenous thrombolysis can achieve a significant degree of recanalization within 3 hours of onset of neurological symptoms.^{160,161} However, it is often difficult to provide thrombolytic therapy within such a narrow time window. Intracarotid delivery of thrombolytic drugs can extend the intervention time window to 6 hours.¹⁶² Intracarotid urokinase, streptokinase and more recently recombinant tissue plasminogen activator have been used for the purpose (table 2).¹⁶³ Development of endovascular clot retrieving devices, laser or ultrasonic clot lysis techniques, and placement endovascular stents can supplement, or provide alternatives, to intracarotid thrombolytic therapy.¹⁶⁴ Intracarotid thrombolysis is superior to intravenous thrombolysis in so far as restoring tissue perfusion, although as yet there is no clear cut evidence of improved neurological outcome with intracarotid thrombolysis in controlled trials (fig. 16).^{165,166} Intracarotid thrombolysis today provides the most compelling reason to investigate intracarotid drug delivery to the brain. The inability to translate the results of preclinical studies with pharmacological treatments of ischemic stroke into effective therapies compels us to develop better methods of drug delivery.¹⁶⁷⁻¹⁶⁹ Intracarotid thrombolysis provides a unique opportunity to deliver drugs at the very site of reperfusion injury and the catheter to do so is already in-situ.

Due to the urgency for interventions, detailed anesthetic assessment may not be feasible in stroke setting. Centers offering intracarotid thrombolysis should have an intervention suite ready to provide immediate anesthesia and should have well established lines of communication between the stroke team and the anesthesiologists. A rapid review of medical history, last meal time, drug treatments and allergies, particularly immediate anti-coagulant treatment has to be undertaken. Airway interventions could be challenging with background anticoagulation due to the potential for hemorrhage from even minor trauma, such as placement of a nasal airway. Wherever feasible, these interventions should be

carried on with minimal sedation to permit neurological examination. However, the condition of the patient could rapidly deteriorate due the evolution of neurological symptoms, or due complications of treatment, such as a hemorrhagic transformation of the infarct, requiring urgent conversion from sedation to general anesthesia. Blood pressure manipulation, particularly induced hypertension, may be required to improve perfusion.²⁹

Miscellaneous uses

Clinicians have frequently used intracarotid drugs to treat life threatening brain diseases but the following applications of intracarotid drugs have not been widely recognized.

Intractable raised ICP

Yokota et al. used low dose bilateral intracarotid infusion of mannitol to treat severely raised intracranial pressure in 18 human subjects with head trauma. They observed that intracarotid mannitol significantly decreased ICP and caused no hemodynamic side effects or disturbances in electrolyte status.¹⁷⁰

Severe intracranial infections

Medical treatment of purulent meningitis and encephalitis is sometimes complicated by the inability to deliver sufficient antibiotics to the infected site.¹⁷¹ In experimental animals, intracarotid hyperosmolar disruption of BBB has been shown to enhance the delivery of tobramycin and vancomycin to the brain.¹⁷² Even without hypertonic disruption, intracarotid antibiotics have yielded beneficial results in treating intracranial infections.^{171,173–175}

Future applications

Intraarterial gene therapy

Perhaps the most potent application of intracarotid drugs in the future is to deliver genes that could alter the course of a disease or help us understand disease processes. Intracarotid delivery of viral vectors, deoxyribonucleic acid bearing liposomes and stem cells have all been successfully demonstrated.^{176,177} Selective delivery of herpes viral vectors to tumor regions by concurrent use of cereport (RMP-7) is one such example.¹⁷⁸ Bone marrow stem cells have been successfully delivered to traumatized regions of the brain after intracarotid injection.¹⁷⁹ Although the field of gene therapy is in its infancy, intracarotid gene delivery could play a key role in the future treatment of brain diseases due to degeneration, ischemia, trauma or neoplasia. Therefore, intracarotid drug delivery promises to play a critical role in emerging areas of molecular and restorative neurosurgery.^{180,181}

Conclusions

Over the last decade, compared to the technical advances in endovascular surgery, the field of intracarotid drug therapies has remained relatively ignored. There is ample anecdotal data to suggest that intracarotid drug therapy is effective for cerebral vasospasm, thromboembolic strokes, and neoplasms. However, there have been few attempts to systematically understand the kinetics of intracarotid drugs. The major efforts to deliver drugs selectively to the brain in the last decade have relied on molecular techniques to

selectively penetrate the BBB (fig. 17). These advances in brain tissue drug targeting by novel neuropharmaceuticals, come at a time of rapid advances in endovascular techniques, material sciences, and brain imaging; that compel us to reevaluate intracarotid drug delivery. Intracarotid drug delivery can instantaneously generate exceedingly high local concentrations of the novel neuropharmaceuticals and thereby assist their regional delivery. Intracarotid drug delivery might be the primary route of drug delivery or it could be used in conjunction with other brain tissue targeting technologies. Therefore, it is time to better understand the kinetics of intracarotid drugs and to develop techniques that could enhance the safety and reliability of such infusions.

Acknowledgments

Funding support: National Institute of Health GM K08 00698 Grant, from the National Institute of Health, Bethesda, Maryland and Irving Clinical Research Career Award from the Irving Center for Clinical Research, New York, New York, (SJ).

This review is dedicated to our parents who despite their hardships, always encouraged us to pursue our dreams. Acknowledgements are due to Mei Wang, M.P.H., Staff Researcher in the Department of Anesthesiology, Columbia University, for her help in preparing this manuscript and the ongoing intracarotid research. We are also thankful to Edward A. Neuwelt, M.D., Professor of Neurology and Neurosurgery at the Oregon Health and Science University, Portland, Oregon for his help with illustrating this review, figure 14.

References

1. Wada J, Rassmussen T. Intracarotid injection of sodium amytal for the lateralization of cerebral speech dominance: Experimental and clinical observations. *J Neurosurg.* 1960; 17:266–82.
2. Fenstermacher J, Gazendam J. Intra-arterial infusions of drugs and hyperosmotic solutions as ways of enhancing CNS chemotherapy. *Cancer Treat Rep.* 1981; 65:27–37. [PubMed: 7346144]
3. Dedrick RL, Oldfield EH, Collins JM. Arterial drug infusion with extracorporeal removal. I. Theoretic basis with particular reference to the brain. *Cancer Treat Rep.* 1984; 68:373–80. [PubMed: 6697327]
4. Neuwelt EA, Pagel M, Barnett P, Glassberg M, Frenkel EP. Pharmacology and toxicity of intracarotid adriamycin administration following osmotic blood-brain barrier modification. *Cancer Res.* 1981; 41:4466–70. [PubMed: 6796261]
5. Oldfield EH, Dedrick RL, Chatterji DC, Yeager RL, Girton ME, Kornblith PL, Doppman JL. Arterial drug infusion with extracorporeal removal. II. Internal carotid carmustine in the rhesus monkey. *Cancer Treat Rep.* 1985; 69:293–303. [PubMed: 2983894]
6. Oldfield EH, Dedrick RL, Yeager RL, Clark WC, DeVroom HL, Chatterji DC, Doppman JL. Reduced systemic drug exposure by combining intra-arterial chemotherapy with hemoperfusion of regional venous drainage. *J Neurosurg.* 1985; 63:726–32. [PubMed: 4056874]
7. Fortin D, Desjardins A, Benko A, Niyonsega T, Boudrias M. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. *Cancer.* 2005; 103:2606–15. [PubMed: 15880378]
8. Miyagami M, Tsubokawa T. Chemotherapy with ACNU and radiation therapy in malignant glioma in cerebral hemisphere of adult. *Gan to Kagaku Ryoho [Japanese J Cancer Chemotherapy].* 1990; 17:1447–53.
9. Perry A, Schmidt RE. Cancer therapy-associated CNS neuropathology: an update and review of the literature. *Acta Neuropathol (Berl).* 2006; 111:197–212. [PubMed: 16463065]
10. Dedrick RL. Arterial drug infusion: pharmacokinetic problems and pitfalls. *J Natl Cancer Instit.* 1988; 80:84–9.
11. Joshi S, Ornstein E, Bruce JN. Targeting the Brain: Rationalizing the novel methods of drug delivery to the central nervous system. *Neurocrit Care.* 2007; 6:200–12. [PubMed: 17572864]

12. Joshi S, Emala CW, Pile-Spellman J. Intra-arterial drug delivery: a concise review. *J Neurosurg Anesthesiol.* 2007; 19:111–9. [PubMed: 17413997]
13. Pile-Spellman, J.; Young, WL. Materials and methods for interventional neuroradiology (INR). In: Taveras, JM., editor. *Neuroradiology.* 3. Vol. Chapter 18.2. Baltimore: Williams & Wilkins; 1996. p. 1047-73.
14. Gobin YP, Cloughesy TF, Chow KL, Duckwiler GR, Sayre JW, Milanese K, Vinuela F. Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery. *Radiology.* 2001; 218:724–32. [PubMed: 11230646]
15. Joshi S, Wang M, Etu JJ, Suckow RF, Cooper TB, Feinmark SJ, Bruce JN, Fine RL. Transient cerebral hypoperfusion enhances intraarterial carmustine deposition into brain tissue. *J Neurooncol.* 2007; 86:123–32. [PubMed: 17634743]
16. Joshi S, Wang M, Etu JJ, Nishanian EV, Pile-Spellman J. Cerebral blood flow affects dose requirements of intracarotid propofol for electrocerebral silence. *Anesthesiology.* 2006; 104:290–8. [PubMed: 16436848]
17. Henk CB, Higgins CB, Saeed M. Endovascular interventional MRI. *J Magn Reson Imaging.* 2005; 22:451–60. [PubMed: 16161076]
18. Allman, JM. *Evolving Brains in Scientific American Library Series.* 1999. The Evolution of Big Brains; p. 158-208.
19. Omojola MF, Fox AJ, Auer RN, Vinuela FV. Hemorrhagic encephalitis produced by selective non-occlusive intracarotid BCNU injection in dogs. *J Neurosurg.* 1982; 57:791–6. [PubMed: 7143062]
20. Crafts DC, Levin VA, Nielsen S. Intracarotid BCNU (NSC-409962): a toxicity study in six rhesus monkeys. *Cancer Treat Rep.* 1976; 60:541–5. [PubMed: 825222]
21. Greenberg HS, Ensminger WD, Seeger JF, Kindt GW, Chandler F, Doan K, Dakhil SR. Intra-arterial BCNU chemotherapy for the treatment of malignant gliomas of the central nervous system: a preliminary report. *Cancer Treat Rep.* 1981; 65:803–10. [PubMed: 7023671]
22. Edvinsson, L.; MacKenzie, ET. *General and Comparative Anatomy of the Cerebral Circulation.* 2. Vol. Chapter 1. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 3-29.
23. Scremin OU, Sonnenschein RR, Rubinstein EH. Cerebrovascular anatomy and blood flow measurements in the rabbit. *J Cereb Blood Flow Metabolism.* 1982; 2:55–66.
24. Lee JS, Hamilton MG, Zabramski JM. Variations in the anatomy of the rabbit cervical carotid artery. *Stroke.* 1994; 25:501–3. [PubMed: 8303763]
25. Roatta S, Roncari S, Micieli G, Bosone D, Passatore M. Doppler sonography to monitor flow in different cerebral arteries in the rabbit. *Exp Physiol.* 2000; 85:431–8. [PubMed: 10918082]
26. Visocchi M, Cuevas DC, Tartaglione T, Mastrojanni G, Cioni B. Inconsistent MRI findings in acute pre-Willisian brain ischemia in rabbit: a useful model? *J Neurosurg Sci.* 1999; 43:93–8. [PubMed: 10735762]
27. Marshall RS, Lazar RM, Mohr JP, Pile-Spellman J, Hacein-Bey L, Duong DH, Joshi S, Chen X, Levin B, Young WL. Higher cerebral function and hemispherical blood flow during awake carotid artery balloon test occlusions. *J Neur Neurosurg Psych.* 1999; 66:734–38.
28. Marshall RS, Lazar RM, Young WL, Solomon RA, Joshi S, Duong DH, Rundek T, Pile-Spellman J. Clinical utility of quantitative cerebral blood flow measurements during internal carotid artery test occlusions. *Neurosurgery.* 2002; 50:996–1004. [PubMed: 11950402]
29. Duong H, Hacein-Bey L, Vang MC, Pile-Spellman J, Joshi S, Young WL. Management of cerebral arterial occlusion during endovascular treatment of cerebrovascular disease. *Problems in Anesthesia: Controversies in Neuroanesthesia.* 1997; 9:99–111.
30. Hillen B. The variability of the circle of Willis: Univariate and bivariate analysis. *Acta Morphol Neerl Scand.* 1986; 24:87–101. [PubMed: 3565095]
31. Hillen B, Hoogstraten HW, Van Overbeeke JJ, Van der Zwan A. Functional anatomy of the circulus arteriosus cerebri (WillisII). *Bull Assoc Anat.* 1991; 75:123–6.
32. Hillen B, Drinkenburg BA, Hoogstraten HW, Post L. Analysis of flow and vascular resistance in a model of the circle of Willis. *J Biomechan.* 1988; 21:807–14.
33. Joshi S, Wang M, Etu JJ, Nishanian EV, Pile-Spellman J. Cerebral blood flow affects dose requirements of intracarotid propofol for electrocerebral silence. *Anesthesiology.* 2006; 104:290–8. [PubMed: 16436848]

34. Joshi S, Wang M, Etu JJ, Pile-Spellman J. Reducing cerebral blood flow increases the duration of electroencephalographic silence by intracarotid thiopental. *Anesth Analg*. 2005; 101:851–8. [PubMed: 16116003]
35. Milburn JM, Moran CJ, Cross DT III, Diringier MN, Pilgram TK, Dacey RG Jr. Effect of intraarterial papaverine on cerebral circulation time. *Am J Neurorad*. 1997; 18:1081–5.
36. Schlosshauer B. The blood-brain barrier: morphology, molecules, and neurothelin. *Bioessays*. 1993; 15:341–6. [PubMed: 8102053]
37. Raub TJ, Kuentzel SL, Sawada GA. Permeability of bovine brain microvessel endothelial cells in vitro: barrier tightening by a factor released from astrogloma cells. *Exp Cell Res*. 1992; 199:330–40. [PubMed: 1347502]
38. Takano S, Yoshii Y, Nose T. Ultrastructure of glioma vessel--morphometric study for vascular permeability. *No to Shinkei - Brain & Nerve*. 1991; 43:49–56. [PubMed: 2054222]
39. Stewart PA, Hayakawa K, Farrell CL. Quantitation of blood-brain barrier ultrastructure. *Microscopy Res Technique*. 1994; 27:516–27.
40. Claudio L. Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. *Acta Neuropathologica*. 1996; 91:6–14. [PubMed: 8773140]
41. Unger RE, Oltrogge JB, von Briesen H, Engelhardt B, Woelki U, Schlote W, Lorenz R, Bratzke H, Kirkpatrick CJ. Isolation and molecular characterization of brain microvascular endothelial cells from human brain tumors. *In Vitro Cellular & Developmental Biology Animal*. 2002; 38:273–81. [PubMed: 12418924]
42. Heistad, DD.; Kontos, HA. Cerebral Circulation. In: Shepherd, JT.; Abboud, FM., editors. *Handbook of Physiology: Section 2: The Cardiovascular System*. Vol. Chapter 5. Bethesda, MD: American Physiological Society; 1983. p. 137-82.
43. Pardridge WM, Yoshikawa T, Kang Y-S, Miller LP. Blood-brain barrier transport and brain metabolism of adenosine and adenosine analogs. *J Pharma Exp Therap*. 1994; 268:14–8.
44. Jolliet-Riant P, Tillement JP. Drug transfer across the blood-brain barrier and improvement of brain delivery. *Fundam Clin Pharmacol*. 1999; 13:16–26. [PubMed: 10027084]
45. Goldstein GW, Betz AL. The blood-brain barrier. *Scientific American*. 1986; 255:74–83. [PubMed: 3749857]
46. Wang M, Joshi S, Emerson RG. Comparison of intracarotid and intravenous propofol for electrocerebral silence in rabbits. *Anesthesiology*. 2003; 99:904–10. [PubMed: 14508324]
47. Jones DR, Hall SD, Jackson EK, Branch RA, Wilkinson GR. Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. *J Pharmacol Exp Ther*. 1988; 245:816–22. [PubMed: 3385643]
48. Pardridge WM, Landaw EM. Tracer kinetic model of blood-brain barrier transport of plasma protein-bound ligands. Empiric testing of the free hormone hypothesis. *J Clin Invest*. 1984; 74:745–52. [PubMed: 6470138]
49. Pardridge WM, Sakiyama R, Fierer G. Blood-brain barrier transport and brain sequestration of propranolol and lidocaine. *Am J Physiol*. 1984; 247:R582–8. [PubMed: 6476152]
50. Urien S, Albengres E, Pinquier JL, Tillement JP. Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin. *Clin Pharma Ther*. 1986; 39:683–9.
51. Riant P, Bree F, Urien S, Hamberger C, Albengres E, Tillement JP. How chronically administered valproate increases chlordiazepoxide transfer through the blood-brain barrier. *Fundamental Clin Pharma*. 1990; 4:105–14.
52. Jolliet P, Simon N, Bree F, Urien S, Pagliara A, Carrupt PA, Testa B, Tillement JP. Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery. *Pharmaceutical Res*. 1997; 14:650–6.
53. Obrist WD, Thompson HK Jr, Wang HS, Wilkinson WE. Regional cerebral blood flow estimated by ¹³³xenon inhalation. *Stroke*. 1975; 6:245–56. [PubMed: 1154462]
54. Obrist, WD.; Dolinskas, CA.; Jaggi, JL.; Cruz, J.; Steiman, DL. Serial cerebral blood flow studies in acute head injury: Application of the intravenous ¹³³ Xe method. 1983. p. 145-50.

55. Sanelli PC, Nicola G, Tsiouris AJ, Ougorets I, Knight C, Frommer B, Veronelli S, Zimmerman RD. Reproducibility of post processing of quantitative CT perfusion maps. *AJR Am J Roentgenol*. 2007; 188:213–8. [PubMed: 17179367]
56. Wang M, Joshi S. Electrocerebral silence after intracarotid propofol injection is a function of transit time. *Anesth Analg*. 2007; 104:1498–503. [PubMed: 17513649]
57. Yamashita J, Handa H, Tokuriki Y, Ha YS, Otsuka SI, Suda K, Taki W. Intra-arterial ACNU therapy for malignant brain tumors. Experimental studies and preliminary clinical results. *J Neurosurg*. 1983; 59:424–30. [PubMed: 6577143]
58. Joshi S, Young WL, Pile-Spellman J, Duong DH, Vang MC, Hacein-Bey L, Lee HT, Ostapkovich N. The feasibility of intracarotid adenosine for the manipulation of human cerebrovascular resistance. *Anesth Analg*. 1998; 87:1291–8. [PubMed: 9842815]
59. Joshi S, Wang M, Etu JJ, Pile-Spellman J. Bolus configuration affects dose requirements of intracarotid propofol for electroencephalographic silence. *Anesth Analg*. 2006; 102:1816–22. [PubMed: 16717331]
60. Khatri P, Neff J, Broderick JP, Khoury JC, Carrozzella J, Tomsick T. Revascularization end points in stroke interventional trials: recanalization versus reperfusion in IMS-I. *Stroke*. 2005; 36:2400–3. [PubMed: 16224088]
61. Kidwell CS, Saver JL, Starkman S, Duckwiler G, Jahan R, Vespa P, Villablanca JP, Liebeskind DS, Gobin YP, Vinuela F, Alger JR. Late secondary ischemic injury in patients receiving intraarterial thrombolysis. *Ann Neurol*. 2002; 52:698–703. [PubMed: 12447922]
62. Murkin JM. Inflammatory responses and CNS injury: implications, prophylaxis, and treatment. *Heart Surg Forum*. 2003; 6:193–5. [PubMed: 12928156]
63. Joshi, S.; Ornstein, E.; Young, WL. Cerebral and Spinal Cord Blood Flow. 4. Vol. Chapter 2. St. Louis, London, Philadelphia, Sidney, Toronto: Mosby; 2002. p. 19-68.
64. Donelli MG, Zucchetti M, D'Incalci M. Do anticancer agents reach the tumor target in the human brain? *Cancer Chemother Pharmacol*. 1992; 30:251–60. [PubMed: 1643692]
65. Mourant JR, Johnson TM, Los G, Bigio IJ. Non-invasive measurement of chemotherapy drug concentrations in tissue: preliminary demonstrations of in vivo measurements. *Phys Med Biol*. 1999; 44:1397–417. [PubMed: 10368027]
66. Hassenbusch SJ, Anderson JH, Colvin OM. Predicted and actual BCNU concentrations in normal rabbit brain during intraarterial and intravenous infusions. *J Neuro-Oncol*. 1996; 30:7–18.
67. Mitsuki S, Diksic M, Conway T, Yamamoto YL, Villemure JG, Feindel W. Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET. *J Neurooncol*. 1991; 10:47–55. [PubMed: 1902507]
68. Tyler JL, Yamamoto YL, Diksic M, Theron J, Villemure JG, Worthington C, Evans AC, Feindel W. Pharmacokinetics of superselective intra-arterial and intravenous [11C]BCNU evaluated by PET. *J Nucl Med*. 1986; 27:775–80. [PubMed: 3486962]
69. Frayne R, Omary RA, Unal O, Strother CM. Determination of optimal injection parameters for intraarterial gadolinium-enhanced MR angiography. *J Vasc Interv Radiol*. 2000; 11:1277–84. [PubMed: 11099237]
70. Hwang KP, Green JD, Li D, Simonetti OP, Resnick SA, Finn JP, Duerk JL, Omary RA. Minimizing contrast agent dose during intraarterial gadolinium-enhanced MR angiography: in vitro assessment. *J Magn Reson Imaging*. 2002; 15:55–61. [PubMed: 11793457]
71. Joshi S, Wang M, Etu J, Nishanian EV. Comparison of intracarotid anesthetics for EEG silence. *J Neurosurg Anesthesiol*. 2006; 18:112–8. [PubMed: 16628064]
72. Humpel C, Ebendal T, Olson L. Microdialysis: a way to study in vivo release of neurotrophic bioactivity: a critical summary. *J Mol Med*. 1996; 74:523–6. [PubMed: 8892057]
73. Layton ME, Wagner JK, Samson FE, Pazdernik TL. Redox changes in perfusates following intracerebral penetration of microdialysis probes. *Neurochem Res*. 1997; 22:735–41. [PubMed: 9178958]
74. Bigio IJ, Bown SG. Spectroscopic sensing of cancer and cancer therapy: current status of translational research. *Cancer Biol Ther*. 2004; 3:259–67. [PubMed: 15107613]

75. Reif R, Wang M, Joshi S, A'Amar O, Bigio IJ. Optical method for real-time monitoring of drug concentrations facilitates the development of novel methods for drug delivery to brain tissue. *J Biomed Opt.* 2007; 12:034–6.
76. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means. *Neurosurgery.* 1998; 42:1083–100. [PubMed: 9588554]
77. Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. *Cellular & Molecular Neurobiol.* 2000; 20:217–30.
78. Neuwelt EA, Minna J, Frenkel E, Barnett PA, McCormick CI. Osmotic blood-brain barrier opening to IgM monoclonal antibody in the rat. *Am J Physiol.* 1986; 250:R875–83. [PubMed: 3706572]
79. Nagashima T, Ikeda K, Wu S, Kondo T, Yamaguchi M, Tamaki N. The mechanism of reversible osmotic opening of the blood-brain barrier: role of intracellular calcium ion in capillary endothelial cells. *Acta Neurochir Suppl (Wien).* 1997; 70:231–3.
80. Siegal T, Rubinstein R, Bokstein F, Schwartz A, Lossos A, Shalom E, Chisin R, Gomori JM. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. *J Neurosurg.* 2000; 92:599–605. [PubMed: 10761648]
81. Zunkeler B, Carson RE, Olson J, Blasberg RG, DeVroom H, Lutz RJ, Saris SC, Wright DC, Kammerer W, Patronas NJ, Dedrick RL, Herscovitch P, Oldfield EH. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. *J Neurosurg.* 1996; 85:1056–65. [PubMed: 8929495]
82. Sato S, Suga S, Yunoki K, Mihara B. Effect of barrier opening on brain edema in human brain tumors. *Acta Neurochir Suppl (Wien).* 1994; 60:116–8. [PubMed: 7976519]
83. Wang M, Etu J, Joshi S. Enhanced disruption of the blood brain barrier by intracarotid mannitol injection during transient cerebral hypoperfusion in rabbits. *J Neurosurg Anesthesiol.* 2007; 19:249–56. [PubMed: 17893577]
84. Tamaki K, Sadoshima S, Heistad DD. Increased susceptibility to osmotic disruption of the blood-brain barrier in chronic hypertension. *Hypertension.* 1984; 6:633–8. [PubMed: 6500670]
85. Ikeda M, Bhattacharjee AK, Kondoh T, Nagashima T, Tamaki N. Synergistic effect of cold mannitol and Na(+)/Ca(2+) exchange blocker on blood-brain barrier opening. *Biochem Biophys Res Commun.* 2002; 291:669–74.
86. Bhattacharjee AK, Nagashima T, Kondoh T, Tamaki N. The effects of the Na(+)/Ca(++) exchange blocker on osmotic blood-brain barrier disruption. *Brain Res.* 2001; 900:157–62. [PubMed: 11334793]
87. Chi OZ, Liu X, Weiss HR. Effects of mild hypothermia on blood-brain barrier disruption during isoflurane or pentobarbital anesthesia. *Anesthesiology.* 2001; 95:933–8. [PubMed: 11605935]
88. Kaya M, Gulturk S, Elmas I, Kalayci R, Arican N, Kocyildiz ZC, Kucuk M, Yorulmaz H, Sivas A. The effects of magnesium sulfate on blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats. *Life Sci.* 2004; 76:201–12. [PubMed: 15519365]
89. Liu R, Wen Y, Perez E, Wang X, Day AL, Simpkins JW, Yang SH. 17beta-Estradiol attenuates blood-brain barrier disruption induced by cerebral ischemia-reperfusion injury in female rats. *Brain Res.* 2005; 1060:55–61. [PubMed: 16212944]
90. Neuwelt EA, Barnett PA, Ramsey FL, Hellstrom I, Hellstrom KE, McCormick CI. Dexamethasone decreases the delivery of tumor-specific monoclonal antibody to both intracerebral and subcutaneous tumor xenografts. *Neurosurgery.* 1993; 33:478–84. [PubMed: 8413880]
91. Kozler P, Pokorny J. Altered blood-brain barrier permeability and its effect on the distribution of Evans blue and sodium fluorescein in the rat brain applied by intracarotid injection. *Physiol Res.* 2003; 52:607–14. [PubMed: 14535837]
92. Kozler P, Pokorny J. Effects of intracarotid injection of methylprednisolone on cellular oedema after osmotic opening of the blood-brain barrier in rats. *Prague Med Report.* 2004; 105:279–90.
93. Chi OZ, Chun TW, Liu X, Weiss HR. The effects of pentobarbital on blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats. *Anesth Analg.* 1998; 86:1230–5. [PubMed: 9620510]
94. Black KL, Cloughesy T, Huang SC, Gobin YP, Zhou Y, Grous J, Nelson G, Farahani K, Hoh CK, Phelps M. Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68

- ethylenediamine tetraacetic acid into human gliomas. *J Neurosurg.* 1997; 86:603–9. [PubMed: 9120622]
95. Chio CC, Baba T, Black KL. Selective blood-tumor barrier disruption by leukotrienes. *J Neurosurg.* 1992; 77:407–10. [PubMed: 1506887]
 96. Joshi S, Meyers P, Pile-Spellman J, Wang M, Sahlein D. Intracarotid Verapamil Decreases both Proximal and Distal Human Cerebrovascular Resistance. *Anesthesiology.* 2004; 100:774–81. [PubMed: 15087610]
 97. Agid R, Rubinstein R, Siegal T, Lester H, Bokstein F, Chisin R, Gomori JM. Does streaming affect the cerebral distribution of infraophthalmic intracarotid chemotherapy? *Ajnr: Am J Neurorad.* 2002; 23:1732–5.
 98. Saris SC, Blasberg RG, Carson RE, deVroom HL, Lutz R, Dedrick RL, Pettigrew K, Chang R, Doppman J, Wright DC. Intravascular streaming during carotid artery infusions. Demonstration in humans and reduction using diastole-phased pulsatile administration. *J Neurosurg.* 1991; 74:763–72. [PubMed: 1849555]
 99. Oldfield EH, Clark WC, Dedrick RL, Egorin MJ, Austin HA, DeVroom HD, Joyce KM, Doppman JL. Reduced systemic drug exposure by combining intraarterial cis-diamminedichloroplatinum(II) with hemodialysis of regional venous drainage. *Cancer Res.* 1987; 47:1962–7. [PubMed: 3815385]
 100. Qureshi AI, Luft AR, Sharma M, Guterman LR, Hopkins LN. Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: Part II--Clinical aspects and recommendations. *Neurosurg.* 2000; 46:1360–75.
 101. Qureshi AI, Luft AR, Sharma M, Guterman LR, Hopkins LN. Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: Part I--Pathophysiological and pharmacological features. *Neurosurg.* 2000; 46:1344–59.
 102. Young WL, Pile-Spellman J. Anesthetic considerations for interventional neuroradiology. *Anesthesiology.* 1994; 80:427–56. [PubMed: 8311325]
 103. Zlotnik EI, Oleshkevich FV. Prolonged catheterization of the superficial temporal artery for repeated angiography. *Vopr Neirokhir.* 1975:43–5. [PubMed: 1199003]
 104. Kallmes DF, McGraw JK, Evans AJ, Mathis JM, Hergenrother RW, Jensen ME, Cloft HJ, Lopes M, Dion JE. Thrombogenicity of hydrophilic and nonhydrophilic microcatheters and guiding catheters. *AJNR Am J Neuroradiol.* 1997; 18:1243–51. [PubMed: 9282849]
 105. Markus H, Loh A, Israel D, Buckenham T, Clifton A, Brown MM. Microscopic air embolism during cerebral angiography and strategies for its avoidance. *Lancet.* 1993; 341:784–7. [PubMed: 8096000]
 106. Saris SC, Wright DC, Oldfield EH, Blasberg RG. Intravascular streaming and variable delivery to brain following carotid artery infusions in the Sprague-Dawley rat. *J Cereb Blood Flow Metab.* 1988; 8:116–20. [PubMed: 3339101]
 107. Lutz RJ, Dedrick RL, Boretos JW, Oldfield EH, Blacklock JB, Doppman JL. Mixing studies during intracarotid artery infusions in an in vitro model. *J Neurosurg.* 1986; 64:277–83. [PubMed: 3944637]
 108. Tonn JC, Roosen K, Schachenmayr W. Brain necroses after intraarterial chemotherapy and irradiation of malignant gliomas--a complication of both ACNU and BCNU? *J Neuro-Oncology.* 1991; 11:241–2.
 109. Di Chiro G, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ, Doppman JL, Larson SM, Ito M, Kufta CV. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. *AJR Am J Roentgenol.* 1988; 150:189–97. [PubMed: 3257119]
 110. Millay RH, Klein ML, Shults WT, Dahlborg SA, Neuwelt EA. Maculopathy associated with combination chemotherapy and osmotic opening of the blood-brain barrier. *Am J Ophthalmol.* 1986; 102:626–32.
 111. Doolittle ND, Miner ME, Hall WA, Siegal T, Jerome E, Osztie E, McAllister LD, Bubalo JS, Kraemer DF, Fortin D, Nixon R, Muldoon LL, Neuwelt EA. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. *Cancer.* 2000; 88:637–47. [PubMed: 10649259]

112. Gelman M, Chakeres DW, Newton HB. Brain tumors: complications of cerebral angiography accompanied by intraarterial chemotherapy. *Radiology*. 1999; 213:135–40. [PubMed: 10540653]
113. Madajewicz S, Chowhan N, Tfayli A, Roque C, Meek A, Davis R, Wolf W, Cabahug C, Roche P, Manzione J, Iliya A, Shady M, Hentschel P, Atkins H, Braun A. Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy. *Cancer*. 2000; 88:2350–6. [PubMed: 10820358]
114. Quyyumi AA, Dakak N, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. *J Clin Invest*. 1995; 95:1747–55. [PubMed: 7706483]
115. Quyyumi AA, Dakak N, Andrews NP, Gilligan DM, Panza JA, Cannon RO. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. *Circulation*. 1995; 92:320–6. [PubMed: 7634444]
116. Stewart DJ, Belanger JM, Grahovac Z, Curuvija S, Gionet LR, Aitken SE, Hugenholtz H, Benoit BG, DaSilva VF. Phase I study of intracarotid administration of carboplatin. *Neurosurgery*. 1992; 30:512–6. [PubMed: 1316564]
117. Fogarty-Mack P, Pile-Spellman J, Hacein-Bey L, Ostapkovich N, Joshi S, Vulliamoz Y, Young WL. Superselective intraarterial papaverine administration: Effect on regional cerebral blood flow in patients with arteriovenous malformations. *J Neurosurg*. 1996; 85:395–402. [PubMed: 8751623]
118. Dedrick RL. Interspecies scaling of regional drug delivery. *J Pharma Sci*. 1986; 75:1047–52.
119. Coubes P, Baldy-Moulinier M, Zanca M, Boire JY, Child R, Bourbotte G, Frerebeau P. Monitoring sodium methohexital distribution with [99mTc]HMPAO with single photon emission computed tomography during Wada test. *Epilepsia*. 1995; 36:1041–9. [PubMed: 7555955]
120. Bazin JE, Picard P, Gabrillargues J, Dordain M. Propofol administered via the carotid artery to achieve a Wada test. *Can J Anaesth*. 1998; 45:707–8. [PubMed: 9717608]
121. Silva TM, Hernandez-Fustes OJ, Bueno ML, Varela AM, Machado S. The Wada test with propofol in a patient with epilepsy. *Arq Neuropsiquiatr*. 2000; 58:348–50. [PubMed: 10849639]
122. Bacia T, Bendarzewska-Nawrocka B, Szymanska O, Dowzenko A, Sadowski Z. A comparison of Wada test for cerebral speech dominance by use of amytal or brietal. *Neurol Neurochir Pol*. 1998; 32 (Suppl 2):247–61. [PubMed: 9757448]
123. Grote CL, Wierenga C, Smith MC, Kanner AM, Bergen DC, Geremia G, Greenlee W. Wada difference a day makes: interpretive cautions regarding same-day injections. *Neurology*. 1999; 52:1577–82. [PubMed: 10331681]
124. Takayama M, Miyamoto S, Ikeda A, Mikuni N, Takahashi JB, Usui K, Satow T, Yamamoto J, Matsushashi M, Matsumoto R, Nagamine T, Shibasaki H, Hashimoto N. Intracarotid propofol test for speech and memory dominance in man. *Neurology*. 2004; 63:510–5. [PubMed: 15304583]
125. Isnard J, Garde P, Fischer C, Duquesnel J, Mauguire F. Clinical and electroencephalographic manifestations during the Wada test using intracarotid injection of methohexital (Brietal). *Rev Neurol*. 1994; 150:266–7. [PubMed: 7863177]
126. Oritano TC, Wascher TM, Reichman OH, Anderson DE. Sustained increased cerebral blood flow with prophylactic hypertensive hypervolemic hemodilution (“Triple-H” Therapy) after subarachnoid hemorrhage. *Neurosurg*. 1990; 27:729–40.
127. Joshi S, Meyers P, Pile-Spellman J, Wang M, Sahlein D. Intracarotid Verapamil Decreases both Proximal and Distal Human Cerebrovascular Resistance. *Anesthesiology*. 2004; 100:774–81. [PubMed: 15087610]
128. Oskouian RJ Jr, Martin NA, Lee JH, Glenn TC, Guthrie D, Gonzalez NR, Afari A, Vinuela F. Multimodal quantitation of the effects of endovascular therapy for vasospasm on cerebral blood flow, transcranial Doppler ultrasonographic velocities, and cerebral artery diameters. *Neurosurgery*. 2002; 51:30–41. [PubMed: 12182433]
129. Smith WS, Dowd CF, Johnston SC, Ko NU, DeArmond SJ, Dillon WP, Setty D, Lawton MT, Young WL, Higashida RT, Halbach VV. Neurotoxicity of intra-arterial papaverine preserved with chlorobutanol used for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. *Stroke*. 2004; 35:2518–22. [PubMed: 15472097]

130. Melamed E, Lavy S. Effect of papaverine on regional cerebral blood flow of the contralateral hemisphere in patients with acute cerebral infarction. *Appl Neurophysiol.* 1979; 42:217–23. [PubMed: 453813]
131. Olesen J, Paulson OB. The effect of intra-arterial papaverine on the regional cerebral blood flow in patients with stroke or intracranial tumor. *Stroke.* 1971; 2:148–59. [PubMed: 5151758]
132. Taylor CL, Selman WR, Ratcheson RA. Steal affecting the central nervous system. *Neurosurgery.* 2002; 50:679–88. [PubMed: 11904017]
133. Boysen G, Engell HC, Pistolese GR, Fiorani P, Agnoli A, Lassen NA. On the critical lower level of cerebral blood flow in man with particular reference to carotid surgery. *Circulation.* 1974; 49:1023–5. [PubMed: 4598629]
134. Hanson E, Anderson R, Sundt T. Influence of cerebral vasoconstricting and vasodilating agents on blood flow in regions of focal ischemia. *Stroke.* 1975; 6:642–8. [PubMed: 812213]
135. Candia GJ, Heros RC, Lavyne MH, Zervas NT, Nelson CN. Effect of intravenous sodium nitroprusside on cerebral blood flow and intracranial pressure. *Neurosurgery.* 1978; 3:50–3. [PubMed: 98731]
136. Joshi S, Hartl R, Wang M, Feng L, Hoh D, Sciacca RR, Mangla S. The acute cerebrovascular effects of intracarotid adenosine in nonhuman primates. *Anesth Analg.* 2003; 97:231–7. [PubMed: 12818972]
137. Cross DT III, Moran CJ, Angtuaco EE, Milburn JM, Diringner MN, Dacey RG Jr. Intracranial pressure monitoring during intraarterial papaverine infusion for cerebral vasospasm. *Am J Neurorad.* 1998; 19:1319–23.
138. Kassell NF, Helm G, Simmons N, Phillips CD, Cail WS. Treatment of cerebral vasospasm with intra-arterial papaverine. *J Neurosurg.* 1992; 77:848–52. [PubMed: 1432125]
139. Joshi S, Hashimoto T, Ostapkovich N, Pile-Spellman J, Duong DH, Hacıen-Bey L, Marshall RS, James DJ, Young WL. Effect of intracarotid papaverine on human cerebral blood flow and vascular resistance during acute hemispheric arterial hypotension. *J Neurosurg Anesthesiol.* 2001; 13:146–51. [PubMed: 11294457]
140. McAuliffe W, Townsend M, Eskridge JM, Newell DW, Grady MS, Winn HR. Intracranial pressure changes induced during papaverine infusion for treatment of vasospasm. *J Neurosurg.* 1995; 83:430–4. [PubMed: 7666218]
141. Mathis JM, DeNardo A, Jensen ME, Scott J, Dion JE. Transient neurologic events associated with intraarterial papaverine infusion for subarachnoid hemorrhage-induced vasospasm. *AJNR Am J Neuroradiol.* 1994; 15:1671–4. [PubMed: 7847211]
142. Mathis JM, DeNardo AJ, Thibault L, Jensen ME, Savory J, Dion JE. In vitro evaluation of papaverine hydrochloride incompatibilities: A simulation of intraarterial infusion for cerebral vasospasm. *Am J Neuroradiol.* 1994; 15:1665–70. [PubMed: 7847210]
143. Ramzan I. Proconvulsant effect of papaverine on theophylline-induced seizures in rats. *Clin Exp Pharmacol Physiol.* 1989; 16:425–7. [PubMed: 2766582]
144. Joshi S, Hashimoto T, Ostapkovich N, Pile-Spellman J, Duong DH, Hacıen-Bey L, Marshall RS, James DJ, Young WL. Effect of intracarotid papaverine on human cerebral blood flow and vascular resistance during acute hemispheric arterial hypotension. *J Neurosurg Anesthesiol.* 2001; 13:146–51. [PubMed: 11294457]
145. McHenry LC Jr, Jaffe ME, Kawamura J, Goldberg HI. Effect of papaverine on regional blood flow in focal vascular disease of the brain. *New Eng J Med.* 1970; 282:1167–70. [PubMed: 4909323]
146. Gogolak I, Gotoh F, Tomita M, Tanahashi N, Kobari M, Shinohara T, Mihara B. No intracerebral steal phenomenon in the ischemic brain following papaverine administration. *Stroke.* 1985; 16:114–7. [PubMed: 3966254]
147. Feng L, Fitzsimmons BF, Young WL, Berman MF, Lin E, Aagaard BD, Duong H, Pile-Spellman J. Intraarterially administered verapamil as adjunct therapy for cerebral vasospasm: safety and 2-year experience. *Ajnr: Am J Neuroradiol.* 2002; 23:1284–90. [PubMed: 12223366]
148. Lavine SD, Wang M, Etu JJ, Meyers PM, Joshi S. Augmentation of cerebral blood flow and reversal of endothelin-1-induced vasospasm: a comparison of intracarotid nicardipine and verapamil. *Neurosurgery.* 2007; 60:742–8. [PubMed: 17415212]

149. Badjatia N, Topcuoglu MA, Pryor JC, Rabinov JD, Ogilvy CS, Carter BS, Rordorf GA. Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. *Ajnr: Am J Neuroradiol.* 2004; 25:819–26. [PubMed: 15140728]
150. Kanamaru K, Waga S, Kuga Y, Nakamura F, Kamata N. Transcranial Doppler pattern after intracarotid papaverine and prostaglandin E1 incorporated in lipid microsphere in patients with vasospasm. *Neurologia Medico-Chirurgica.* 1998; 38 (Suppl):152–5. [PubMed: 10234998]
151. Nakamura T, Tataru N, Morisaki K, Kawakita K, Nagao S. Cerebral oxygen metabolism monitoring under hypothermia for severe subarachnoid hemorrhage: report of eight cases. *Acta Neurol Scand.* 2002; 106:314–8. [PubMed: 12371927]
152. Ding Y, Li J, Rafols JA, Phillis JW, Diaz FG. Prereperfusion saline infusion into ischemic territory reduces inflammatory injury after transient middle cerebral artery occlusion in rats. *Stroke.* 2002; 33:2492–8. [PubMed: 12364743]
153. Ding Y, Yao B, Zhou Y, Park H, McAllister JP 2nd, Diaz FG. Prereperfusion flushing of ischemic territory: a therapeutic study in which histological and behavioral assessments were used to measure ischemia-reperfusion injury in rats with stroke. *J Neurosurg.* 2002; 96:310–9. [PubMed: 11838805]
154. Wagner KR, Zuccarello M. Local brain hypothermia for neuroprotection in stroke treatment and aneurysm repair. *Neurol Res.* 2005; 27:238–45. [PubMed: 15845207]
155. Fontaine S, Theron J, Melanson D, Villemure JG, Emrich J, Raymond J, Ethier R. Superselective cerebral arterial infusion of BCNU in high-grade glioma: the radiologist's point of view. *Can Assoc Radiol J.* 1988; 39:178–81. [PubMed: 2971050]
156. Cloughesy TF, Gobin YP, Black KL, Vinuela F, Taft F, Kadkhoda B, Kabbinavar F. Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow. *J Neurooncol.* 1997; 35:121–31. [PubMed: 9266448]
157. Saris SC, Shook DR, Blasberg RG, Dedrick RL, Doppman JL, Bankiewicz KS, Blacklock JB, Oldfield EH. Carotid artery mixing with diastole-phased pulsed drug infusion. *J Neurosurg.* 1987; 67:721–5. [PubMed: 3668642]
158. Roman-Goldstein S, Mitchell P, Crossen JR, Williams PC, Tindall A, Neuwelt EA. MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy. *AJNR Am J Neuroradiol.* 1995; 16:543–53. [PubMed: 7793380]
159. Elkassabany N, Bhatia J, Deogaonkar A, Barnette G, Ferece S, Lotto M, Murtua M, Ebrahim Z, Schubert A, Farga E. Anesthetic Management of Blood Brain Barrier Disruption (BBBD). A Retrospective Review (Abstract). *J Neurosurg Anesthesiol.* 2005; 17:240.
160. Jahan R. Hyperacute therapy of acute ischemic stroke: intraarterial thrombolysis and mechanical revascularization strategies. *Techn Vasc Intervent Radiol.* 2005; 8:87–91.
161. Jahan R, Vinuela F. Intraarterial thrombolysis for acute ischemic stroke. *Adv in Neurol.* 2003; 92:383–7.
162. Keris V, Rudnicka S, Vorona V, Enina G, Tilgale B, Fricbergs J. Combined intraarterial/intravenous thrombolysis for acute ischemic stroke. *Ajnr: Am J Neuroradiol.* 2001; 22:352–8. [PubMed: 11156782]
163. Mielke O, Wardlaw J, Liu M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. *Cochrane Database Syst Rev.* 2004;CD000514. update of Cochrane Database Syst Rev. 2000;(2):CD000514. [PubMed: 15494998]
164. Mahon BR, Nesbit GM, Barnwell SL, Clark W, Marotta TR, Weill A, Teal PA, Qureshi AI. North American clinical experience with the EKOS MicroLysUS infusion catheter for the treatment of embolic stroke. *Ajnr: Am J Neuroradiol.* 2003; 24:534–8. [PubMed: 12637311]
165. Bourekas EC, Slivka AP, Shah R, Sunshine J, Suarez JJ. Intraarterial thrombolytic therapy within 3 hours of the onset of stroke. *Neurosurgery.* 2004; 54:39–44. [PubMed: 14683539]
166. Lee DH, Jo KD, Kim HG, Choi SJ, Jung SM, Ryu DS, Park MS. Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study. *J Vasc Interv Radiol.* 2002; 13:769–74. [PubMed: 12171979]
167. Neuroprotection the end of an era? *Lancet.* 2006; 368:1548.
168. Del Zoppo GJ. Why do all drugs work in animals but none in stroke patients? 1. Drugs promoting cerebral blood flow [Review]. *J Intern Med.* 1995; 237:79–88. [PubMed: 7830035]

169. Grotta J. Neuroprotection is unlikely to be effective in humans using current trial designs. *Stroke*. 2002; 33:306–7. [PubMed: 11779929]
170. Yokota H, Nakabayashi M, Fuse A, Mashiko K, Yamamoto Y, Henmi H, Otsuka T. Continuous intracarotid infusion of mannitol in severe head injury [Japanese]. *No Shinkei Geka* [Neurological Surgery]. 1993; 21:205–11.
171. Domanskaia IA, Kukushkin AA, Mazurok, Il'in KL. Regionarnoe primeneniye antibiotikov pri lechenii cherepno-mozgovoi travmy i gnoinykh oslozhnenii. *Vestn Khir Im I I Grek*. 1993; 150:53–6. [PubMed: 8379080]
172. Perkins BA, Strausbaugh LJ. Effect of mannitol infusions into the internal carotid artery on entry of two antibiotics into the cerebrospinal fluid and brains of normal rabbits. *Antimicrob Agents Chemotherapy*. 1983; 24:339–42.
173. Kudriavtsev AE, Shikov VG. Primeneniye karotidnoi infuzii lekarstvennykh veshchestv dlia lecheniia bol'nykh gnoinykh meningitom. *Sovetskaia Meditsina*. 1976:55–7. [PubMed: 968612]
174. Draliuk NS, Draliuk MG. Dlitel'naia intrakarotidnaia infuziia v neirokhirurgii. *Voprosy Neirokhirurgii*. 1986:54–7.
175. Mozhaev SV, Zubkov Iu N, Ponomarev AM, Shimchenko P. Nekotorye voprosy kliniki i kompleksnogo lecheniia septicheskikh trombozov kavernozykh sinusov. *Vestnik Khirurgii Imeni i - i - Grekova*. 1980; 125:43–50. [PubMed: 7414892]
176. Rainov NG, Ikeda K, Qureshi NH, Grover S, Herrlinger U, Pechan P, Chiocca EA, Breakefield XO, Barnett FH. Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. *Human Gene Ther*. 1999; 10:311–8. [PubMed: 10022555]
177. Chauvet AE, Kesava PP, Goh CS, Badie B. Selective intraarterial gene delivery into a canine meningioma. *J Neurosurg*. 1998; 88:870–3. [PubMed: 9576256]
178. Barnett FH, Rainov NG, Ikeda K, Schuback DE, Elliott P, Kramm CM, Chase M, Qureshi NH, Harsh Gt, Chiocca EA, Breakefield XO. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. *Cancer Gene Ther*. 1999; 6:14–20. [PubMed: 10078959]
179. Lu D, Li Y, Wang L, Chen J, Mahmood A, Chopp M. Intraarterial administration of marrow stromal cells in a rat model of traumatic brain injury. *J Neurotrauma*. 2001; 18:813–9. [PubMed: 11526987]
180. Amar AP, Zlokovic BV, Apuzzo ML. Endovascular restorative neurosurgery: a novel concept for molecular and cellular therapy of the nervous system. *Neurosurgery*. 2003; 52:402–12. [PubMed: 12535371]
181. Zlokovic BV, Apuzzo ML. Cellular and molecular neurosurgery: pathways from concept to reality--part II: vector systems and delivery methodologies for gene therapy of the central nervous system. *Neurosurgery*. 1997; 40:805–12. [PubMed: 9092854]
182. Suzuki S, Ito O, Savama T, Yamaguchi S, Goto K, Sasaki T. Intraarterial injection of cloforsin daropate hydrochloride for treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage: preliminary report of two cases. *Neuroradiology*. 2006; 48:50–3. [PubMed: 16261335]
183. Fortin D, Osztie E, Neuwelt EA. Iatrogenic arterial spasm relieved by intraarterial mannitol infusion. *Ajnr: Am J Neuroradiol*. 2000; 21:968–70. [PubMed: 10815679]
184. Bejjani GK, Duong DH, Kalamarides M, Ziyal I, Sullivan BJ. Cerebral vasospasm after tumor resection. A case report. *NeuroChirurgie*. 1997; 43:164–8. [PubMed: 9696892]
185. Fandino J, Kaku Y, Schuknecht B, Valavanis A, Yonekawa Y. Improvement of cerebral oxygenation patterns and metabolic validation of superselective intraarterial infusion of papaverine for the treatment of cerebral vasospasm. *J Neurosurg*. 1998; 89:93–100. [PubMed: 9647178]
186. Touho H, Furuoka N, Karasawa J. Distribution of intraarterially administered papaverine in endovascular treatment of delayed cerebral vasospasm. *Neurol Med Chir (Tokyo)*. 1997; 37:163–71. [PubMed: 9059039]
187. Yoshida K, Watanabe H, Nakamura S. Intraarterial injection of amrinone for vasospasm induced by subarachnoid hemorrhage. *AJNR Am J Neuroradiol*. 1997; 18:492–6. [PubMed: 9090409]

188. Clouston JE, Numaguchi Y, Zoarski GH, Aldrich EF, Simard JM, Zitnay KM. Intraarterial papaverine infusion for cerebral vasospasm after subarachnoid hemorrhage. *Am J Neuroradiol.* 1995; 16:27–38. [PubMed: 7900600]
189. Miller JA, Cross DT, Moran CJ, Dacey RG Jr, McFarland JG, Diringner MN. Severe thrombocytopenia following intraarterial papaverine administration for treatment of vasospasm. *J Neurosurg.* 1995; 83:435–7. [PubMed: 7666219]
190. Morgan MK, Day MJ, Little N, Grinnell V, Sorby W. The use of intraarterial papaverine in the management of vasospasm complicating arteriovenous malformation resection: Report of two cases. *J Neurosurg.* 1995; 82:296–9. [PubMed: 7815162]
191. Nakagawa H, Fujita T, Kubo S, Tsuruzono K, Yamada M, Tokiyoshi K, Miyawaki Y, Kanayama T, Kadota T, Hayakawa T. Selective Intra-arterial chemotherapy with a combination of etoposide and cisplatin for malignant gliomas: Preliminary report. *Surg Neurol.* 1994; 41:19–27. [PubMed: 8310382]
192. Kaku Y, Yonekawa Y, Tsukahara T, Kazekawa K. Superselective intra-arterial infusion of papaverine for the treatment of cerebral vasospasm after subarachnoid hemorrhage. *J Neurosurg.* 1992; 77:842–7. [PubMed: 1432124]
193. Boker DK, Solymosi L, Wassmann H. Immediate postangiographic intraarterial treatment of cerebral vasospasm after subarachnoid hemorrhage with nimodipine. Report on 3 cases. *Neurochirurgia.* 1985; 28 (Suppl 1):118–20. [PubMed: 4010867]
194. Abou-Chebl A, Bajzer CT, Krieger DW, Furlan AJ, Yadav JS. Multimodal therapy for the treatment of severe ischemic stroke combining GPIIb/IIIa antagonists and angioplasty after failure of thrombolysis. *Stroke.* 2005; 36:2286–8. [PubMed: 16179581]
195. Zaidat OO, Suarez JJ, Sunshine JL, Tarr RW, Alexander MJ, Smith TP, Enterline DS, Selman WR, Landis DM. Thrombolytic therapy of acute ischemic stroke: correlation of angiographic recanalization with clinical outcome. *Ajnr: Am J Neuroradiol.* 2005; 26:880–4. [PubMed: 15814938]
196. Li SM, Miao ZR, Zhu FS, Wang ML, Hua Y, Dong Y, Song QB, Ling F. Combined intraarterial thrombolysis and intra-cerebral stent for acute ischemic stroke institute of brain vascular diseases. *Chung-Hua i Hsueh Tsa Chih.* 2003; 83:9–12. [PubMed: 12757636]
197. Rabinstein AA, Wijedicks EF, Nichols DA. Complete recovery after early intraarterial recombinant tissue plasminogen activator thrombolysis of carotid T occlusion. *Ajnr: Am J Neuroradiol.* 2002; 23:1596–9. [PubMed: 12372754]
198. Fukuda I, Gomi S, Meguro K, Wada M. Impact of immediate cerebral angiography for in-hospital cerebral thromboembolism after cardiovascular surgery. *Japan J Thorac Cardiovasc Surg.* 2001; 49:282–6. [PubMed: 11431946]
199. Kase CS, Furlan AJ, Wechsler LR, Higashida RT, Rowley HA, Hart RG, Molinari GF, Frederick LS, Roberts HC, Gebel JM, Sila CA, Schulz GA, Roberts RS, Gent M. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. *Neurology.* 2001; 57:1603–10. [PubMed: 11706099]
200. Sylaja PN, Kuruttukulam G, Joseph S, Gupta AK, Radhakrishnan K. Selective intra arterial thrombolysis in acute carotid territory stroke. *Neurol India.* 2001; 49:153–7. [PubMed: 11447435]
201. Suwanwela NC, Phanthumchinda K, Suwanwela N, Tantivatana J, Janchai A. Thrombolytic treatment for acute ischemic stroke: a 2 year-experience at King Chulalongkorn Memorial Hospital. *J Med Assoc Thai.* 2001; 84 (Suppl 1):S428–36. [PubMed: 11529370]
202. Endo S, Kuwayama N, Hirashima Y, Akai T, Nishijima M, Takaku A. Results of urgent thrombolysis in patients with major stroke and atherothrombotic occlusion of the cervical internal carotid artery. *AJNR Am J Neuroradiol.* 1998; 19:1169–75. [PubMed: 9672034]
203. Jahan R, Duckwiler GR, Kidwell CS, Sayre JW, Gobin YP, Villablanca JP, Saver J, Starkman S, Martin N, Vinuela F. Intraarterial thrombolysis for treatment of acute stroke: experience in 26 patients with long-term follow-up. *AJNR Am J Neuroradiol.* 1999; 20:1291–9. [PubMed: 10472989]
204. Barr JD, Mathis JM, Wildenhain SL, Wechsler L, Jungreis CA, Horton JA. Acute stroke intervention with intraarterial urokinase infusion. *J Vascular Intervent Radiol.* 1994; 5:705–13.

205. Casto L, Moschini L, Camerlingo M, Gazzaniga G, Partiguain T, Belloni G, Mamoli A. Local intraarterial thrombolysis for acute stroke in the carotid artery territories. *Acta Neurol Scand.* 1992; 86:308–11. x. [PubMed: 1414252]

Summary Statement

Rapid advances in endovascular surgery now compel us to take a second look at intracarotid drug delivery. This review describes the principles, potential applications, and limitations of intracarotid drug delivery for diagnostic and therapeutic procedures.

Figure 1. Some variations in the anatomy of the Circle of Willis in human subjects

A complete balanced circle is seen in 18% of the general population. Hypoplastic segment of the posterior cerebral artery (PCoA) is seen in 22%. Hypoplastic segment of the anterior cerebral artery (A1) is seen in 25%. A fetal posterior cerebral artery (fetal PCA) with hypoplastic PCA is seen in 15%.²⁹ ACA: anterior cerebral artery, middle cerebral artery: middle cerebral artery, PCA: posterior cerebral artery and BA: basilar Artery.²⁹ Reproduced with permission.²⁹

Figure 2. Schematic representations of the compartments in the brain and the complex kinetics of intracarotid drug delivery
 Brain parenchyma is not a homogenous entity and is separated into gray and white matter. Bi-directional arrows represent the “diffusivity of the drugs” within the brain parenchyma. Pathological lesion (Pathology) may create additional tissue compartments. Three barriers separate the compartments: blood-brain, blood-Cerebral spinal fluid (CSF), and CSF-brain. Of the three, the blood brain barrier is the most significant. Reproduced with permission ⁷¹

Figure 3. Model of intracarotid drug delivery

C_1 , C_2 and V_1 , V_2 are the concentrations and volumes in a brain (1) and the remaining body (2), respectively. Q is the arterial blood flow and venous return. CL_1 and CL_2 are the cerebral and the remaining body clearances. Reproduced with permission ¹⁰

Figure 4. Micro-pharmacokinetics of drug delivery to the brain

Potential factors that could affect drug concentrations at its specific site of action. Reproduced with permission ⁵⁶

Figure 5. Disruption of the Blood Brain Barrier (BBB) with intracarotid mannitol

The figure shows the disruption of the BBB by intracarotid injection of mannitol (25%) in New Zealand White rabbits as evidenced by the distribution of 2% Evans blue dye: mannitol **A**: 2 ml, **B**: 4 ml, **C**: 6 ml, and **D**: 8 ml bolus injected through the carotid artery in one minute. Reproduced with permission ⁸³

Figure 6. a–d: Super-selective placement of microcatheters in the distal regions of the brain

Microcatheters 1.2–1.8 French sizes can be navigated into the distal brain for delivering drugs, measuring physiological parameters, such as pressure and blood flow, and repairing blood vessels. Typically two to three coaxial catheters are used. The first catheter, not shown in the figure, is located in the femoral artery (the introducer sheath). The second catheter is placed in the Internal carotid artery (ICA) guiding catheter and the third catheter (microcatheter) is guided in the distal regions of the brain, Figure A. In this example, catheters are being used for measuring change in arterial blood pressure, Cerebral blood flow (CBF) and CBF velocity to determine the site of effect of intracarotid vasodilators. Figure B and C show the placement of detectors. The model can be used to determine changes in proximal arterial resistance and can estimate changes in the cerebral arteries that lie distally beyond the tip of the microcatheter, Figure D. Reproduced with permission ⁹⁶

Figure 7. Effect of blood flow on the dose requirements of intracarotid propofol

Intraarterial verapamil is a potent cerebral vasodilator. **A:** The dose of intracarotid propofol required to produce 10 min of electrocerebral (EEG) silence significantly increases with verapamil pretreatment ($n=14$, $P=0.004$). **B:** The dose requirement of propofol is linearly related to the increase in blood flow after verapamil pretreatment ($r=0.75$, $P=0.0021$). **C:** Increase in cerebral blood flow with changes in ventilation directly affects the dose of propofol required for electrocerebral silence. Abbreviations:

HYO: hypocapnia, HYR: hypercapnia and NOR: normocapnia. Reproduced with permission³³

Figure 8. Increase in the duration of EEG silence with intracarotid anesthetic drugs injected during transient cerebral hypoperfusion (CHP)

The duration of EEG silence after intracarotid injection of thiopental (3mg as 1% solution, **A**) and propofol (3mg as 1% solution, **B**). In figures thiopental 1 and 3, and, propofol 1 and 3, injections were undertaken with normal blood flow; while the second injections (thiopental-2 and propofol-2) were made during transient CHP. During transient CHP the blood flow decreased to 10–20% of baseline for <60 sec. The effects of the anesthetics were significantly prolonged when they were injected during CHP. Reproduced with permission ³⁴¹⁶

Figure 9. Factors that influence the extent of streaming in an in-vitro model of human cerebral arteries

A: shows streaming of the dye (2ml/min) from a P-100 catheter in a supra-optalmic position (arrow). Note that there is a clear stream of dye in the anterior choroidal artery (ACh A) and that there is no flow of the dye to the anterior cerebral artery (ACA).

B: Shows a more homogeneous dispersion of the dye when it is injected in an infra-optalmic location at a rate of 17 ml/min. A proximal site and a high rate volume rate of infusion, decrease the variability in drug concentration due to streaming.

Reproduced with permission ¹⁰⁷

Figure 10. Effect of flow rate on distribution of the drug

Reconstructed autoradiographic images showing the distribution of the tracer in the brains of monkeys with a steady state infusion equal to 1–2% (a, b, and c) or 20% (d, e and f) of the intracarotid artery (ICA) blood flow volume. Tracer was more evenly distributed with higher flows. Reproduced with permission ¹⁵⁷

Figure 11. Super-selective Wada a case report

A 32 year old woman with seizures and left hemicranial headaches was found to harbor a subcortical arteriovenous malformation (AVM) in the left parietal lobe. A: Left carotid arteriography confirmed the presence of the AVM with multiple nidus aneurysms (arrow). B: Under local anesthesia only a 0.5 mm diameter microcatheter was placed in close proximity of the AVM for the injection of anesthetic drugs, amytal and lidocaine, for super-selective Wada testing. The testing is performed in conjunction with members of the neuropsychological service to determine the risk of causing neurological deficits both at embolization or surgical resection. In this case no changes in function were identified. C: Fluoro-angiography of the cranium following the occlusion of the AVM with n-butyl-cyanoacrylate (NBCA glue) shows radio-opaque glue filling the sinusoids within the AVM nidus (arrow). D: Control angiography following occlusion of the AVM shows complete obliteration of the AVM nidus and no other branch vessel occlusion (arrow). The patient tolerated embolization and resection without any complication and returned to work in 9 days. Images and case history are provided by Phillip M Meyers, MD.

Figure 12. Treatment of cerebral vasospasm with intracarotid verapamil

A 57 year old woman developed sudden severe headache and collapsed to the floor. On admission to the hospital emergency department, she was comatose with decorticate posturing. **A**, CT brain scan without contrast demonstrates diffuse subarachnoid hemorrhage (*arrow*). **B and C**, Cerebral arteriography demonstrates a 7 mm left posterior communicating artery aneurysm (*arrow*). There is no spasm in the cerebral arteries at the time of initial presentation. **D**, Surveillance arteriography on day 7 following the hemorrhage shows moderate to severe, flow-limiting spasm of the cerebral arteries (*arrows*). **E**, To prevent stroke, endovascular treatment including balloon angioplasty (*arrow*) followed by vasodilator infusion therapy with verapamil 5 mg was performed. **F**, Cerebral arteriography following treatment shows both improved vessel dimension and flow in the cerebral vasculature. Images and case history are provided by Phillip M Meyers, MD.

Figure 13. Effects of adenosine on human cerebral blood flow (CBF)

Adenosine is rapidly metabolized by the vascular endothelium and the red blood cells with an elimination half-life of 1–10 seconds. An intracarotid bolus of 1–2 mg of adenosine results in significant change in shape of the ^{133}Xe washout curve. Compare the washouts during injection of adenosine, nicardipine and saline, figure A. The effects of adenosine bolus seem to last for less than 30 seconds. The conventional CBF measurements (standard initial slope analysis or standard ISI) that is measured between 20 to 80 seconds after ^{133}Xe injection, fail to show an increase in CBF (solid circles, Figure B, C) with intracarotid adenosine. However, early initial slope analysis (early ISI) that is measured between 5–25 s after ^{133}Xe , (solid squares, figure B, C) seem to have a dramatic effect on CBF. In case of nicardipine, a longer acting drug, the early ISI and standard ISI yield similar results. Effects of intracarotid adenosine on CBF are exceedingly transient while nicardipine has a sustained effect. Reproduced with permission ⁵⁸

Figure 14. Response of a lymphoid tumor to intracarotid chemotherapy

A 62 year old right-handed woman presented with three symptomatic white chorioretinal lesions in the right eye. A vitreal biopsy showed small lymphoid cells. Six months later the patient started experiencing problem while walking. MRI revealed contrast-enhancing lesion in the brain (A–D). A stereotactic brain biopsy showed large B-cell lymphoma, CD20 – positive. CSF contained 20 atypical cells/ml. She underwent first treatment with blood brain barrier disruption with intracarotid mannitol and intraarterial Methotrexate, and Carboplatin that was supplemented with intravenous Rituxan. She was admitted every 4 weeks for 2 consecutive days of the same treatment with barrier opening and intraarterial chemotherapy in one of the major brain feeding artery the left or the right internal carotid or the vertebral artery. The patient was also treated with intraocular Rituxan and Methotrexate. After 8 courses of treatment there was radiological evidence of complete tumor regression (E–H) without any neurologic symptoms, or evidence of intraocular disease. Images and case history are courtesy of Edward A. Neuwelt, M.D., Professor of Neurology and Neurosurgery, Oregon Health and Science University, Portland, Oregon.

Figure 15. Intracarotid injection of embolic materials to facilitate surgery of brain tumors

A 39 year old man with Neurofibromatosis Type II, a condition that often results in early development of multiple brain tumors presented with hearing loss and seizures. In addition to small bilateral tumors of the vestibular nerves (not shown), the patient had developed a large extra-axial mass most compatible with a meningioma, a benign tumor that arises from the dura matter or brain covering (A white arrow). Meningiomas are often highly vascular tumors. Prior to surgical removal of the tumor, the patient underwent cerebral angiography that demonstrated that blood supply to the tumor arose from branches of the middle meningeal artery (B, white arrow). With the patient awake and in a painless manner, a tiny microcatheter was advanced into the branches of the middle meningeal artery supplying the tumor (C, black arrow), and the tumor was embolized. Arteriography after embolization demonstrates that there is no longer any blood flowing to the tumor (D, white circle) indicating that the tumor could now be surgically resected with minimal blood loss. Images and case history are provided by Phillip M Meyers, MD.

Figure 16. Intracarotid thrombolysis in acute stroke

A 62 year old woman with multiple cardiovascular risk factors, presented with quadriplegia followed by loss of consciousness.

A, Left vertebral arteriography demonstrates distal occlusion of the basilar artery (arrow). B: On high magnification angiography, the filling defect resulting from the occlusive thromboembolism is evident. (arrow). C: Microcatheter arteriography in the lateral projection further delineates the site of occlusion prior to thrombolysis with the plasminogen activator, urokinase. D: Following lysis of the occlusive thrombus, complete restoration of flow in the vertebrobasilar system has been restored. Images and case history are provided by Phillip M Meyers, MD.

Figure 17.

Techniques of selective delivery of drugs to the brain that are currently under development. These techniques generally target unique features of the blood brain barrier (BBB) such as specific molecules or transport mechanisms. Intracarotid delivery can enhance the effectiveness of these techniques by increasing the speed of onset of drug effects and delivering exceedingly high first pass concentrations. Reproduced with permission ¹²

Table 1
Selected Reports of Intracarotid Vasodilators for the Treatment Of Human Cerebral Vasospasm

Author	Subjects (n)	Intervention/Drug	Significant Complications	Outcome	Ref.
Suzuki 2006	(2)	Cloforsin		Improved	182
Oskouian 2002	45	IAP ± stenting		Combined therapy more useful.	128
Feng 2002	SAH vasospasm (29)	IA-verapamil (3- mg)	No hemodynamic complications	5/29 improved.	147
Fortin 2000	Catheter induced spasm (1)	10 ml of 25% mannitol	None	Improved	183
Bejjani 1999	Incidence after skull base surgery is 1.9%	angioplasty + papaverine 5/8 papaverine 1/8 HHH8/8		6/8 improved	184
Cross 1998	SAH vasospasm (28)	IAP 300 mg/vessel	Baseline ICP 15 mm greater risk intracranial hypertension with IAP.	Increased ICP with IAP reported, ICP monitoring essential	137
Fandino 1998	SAH vasospasm (10)	IAP +HHH	Combined therapy more effective	Improved jugular bulb oxygenation and reversal of lactic acidosis	185
Milburn 1997	SAH vasospasm (27)			IAP decreased transit time in 58/59 territories	35
Touho 1997	SAH vasospasm	IAP and HMPAO		Super-selective catheterization not necessary for ACA delivery	186
Yoshida 1997	SAH vasospasm (2)	Intracarotid amrinone		Angiographic response	187
Mathis 1994	SAH vasospasm (3)	IAP 300 mg	worsening in all 3, coma resp arrest,	1 improved	141
Clouston 1995	SAH vasospasm (14)	60 vascular territories: IAP 150-600 mg	1 transient blindness 1 seizure 1 vascular complication	7/14 markedly improved	188
Miller 1995	SAH vasospasm (1)	IAP 300 mg	Thrombocytopenia	Improved	189
Morgan 1995	post AVM resection (2)	IAP 150-250 mg	1 had neurological deterioration	2/2 improved	190
Nakagawa 1994	Vasospasm during IA chemotherapy (20)	IAP with nicardipine in 12/20 cases,		Lower concentration of chemo-therapeutic agents decreased complications	191
Kaku 1992	SAH vasospasm (10)	IAP 200 mg with nicardipine		8/10 patients improved	192
Kassell 1992	SAH vasospasm (10)	IAP 100-300 mg	2 had transient neurological deficits	8/12 angiographic response; 4/12 improved	138
Boker 1985	SAH+ vasospasm: (3)	Nimodipine (0.3 mg)	none	Angiographic response	193

AVM: arteriovenous malformation, HHH: Hypervolemic-hemodilution and hypertension, IA: Intraarterial; IAP: intracarotid papaverine; SAH: subarachnoid hemorrhage.

Table 2
Selected Clinical Reports Describing Use of Intracarotid Thrombolytics for Ischemic Stroke

	Number of patients	Time/Setting	Drug and Dose	Complications	Outcome	Ref.
Khatri 2005	61 angiograms	Acute stroke	IV and IA rTPA		49–54% improved. Clinical outcome was related to degree of revascularization	60
Abou-Chebl 2005	12 patients	3.8±2.2 hr	IA rTPA, IA or IV abciximab, heparin and stent	1/12 hemorrhagic infarction	11/12 good recovery	194
Zaidat 2005	96 patients	Acute stroke	IA or combined IV and IA rTPA	ICH 7.6 to 13.3%	24–69% recanalization was a function of time to treatment.	195
Bourekas	36 patients	<3hr	IA	11% ICH	75% recanalization	165
Li 2003	19 patients	Acute stroke	IA thrombolysis+ stent		18/19 no stenosis	196
Lee 2002	26 patients	Acute stroke	IA urokinase alone (16), IA Urokinase with IV abciximab		Abciximab increased the recanalization rate and decreased the urokinase dose.	166
Rabinstein 2002	1 patients	<3hr	IA-rTPA		Complete recovery	197
Keris 2001	12 treated 33 controls patients	<6hr	rTPA (actilyse) 50 mg IA initially and IV subsequently	ICH	Good outcome in 66% in treatment group vs 21% in control	162
Fukuda 2001	5 patients	< 6hr	IA thrombolysis in 3/5		Recanalization achieved in all 3	198
Kase 2001	120 of the 180 patients	<6 hr	IA pro-urokinase	ICH in 10.9% with 83 % mortality		199
Sylaja 2001	5 patients		IA-urokinase		2 patients treated within 3 hours had complete recovery.	200
Suwanwela 2001	2 patients	<6hr	IA-rTPA		2/2 angiographic but not clinical recovery	201
Endo 1998	33 patients	<6hr	IA thrombolysis		Good prognosis with treatment <3hr followed by stent or angioplasty	202
Jahan 1999	26 patients	<6 hr	IA TPA	Hemorrhage in 10/26	11/26 partial or complete recanalization, 9 had good outcome. 15/26 little or no recanalization	203
Barr 1994	12 patients	<8hr	Urokinase (160–500 K Units)	3/12 failed	9/12 Recanalized	204
Casto 1992	5 patients	<5hr	Urokinase 560K units		4/5 Recanalized	205

IA: Intracarotid; ICH: Intracranial hemorrhage; IV: Intravenous; rTPA: Recombinant tissue plasminogen activator